Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. by Fassnacht, M et al.
1 
ESE and ENSAT guideline on adrenal incidentaloma v.21.3.2016 
Management of adrenal incidentalomas 1 
- a European Society of Endocrinology Clinical Practice 2 
Guideline in collaboration with the European Network for the 3 
Study of Adrenal Tumors 4 
 5 
Martin Fassnacht1,2, Wiebke Arlt3,4, Irina Bancos3,4,5, Henning Dralle6, 6 
John Newell-Price7,8, Anju Sahdev9, Antoine Tabarin10, Massimo Terzolo11, 7 
Stylianos Tsagarakis12, Olaf M. Dekkers13,14 8 
 9 
1 Department of Internal Medicine I, Division of Endocrinology and Diabetes, University 10 
Hospital, University of Würzburg, Würzburg Germany 11 
2 Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.  12 
3 Institute of Metabolism & Systems Research, University of Birmingham, Birmingham, B15 13 
2TT, UK 14 
4 Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, 15 
Birmingham, B15 2TH, UK 16 
5 Division of Endocrinology, Metabolism, Nutrition and Diabetes, Mayo Clinic, Rochester, MN, 17 
USA 18 
6 Department of General, Visceral, and Vascular Surgery, Martin-Luther-University Halle-19 
Wittenberg, Halle (Saale), Germany 20 
7 Department of Oncology and Metabolism, Medical School, University of Sheffield, S10 2RX, 21 
UK 22 
8 Endocrine Unit, Royal Hallamshire Hospital, Sheffield Teaching Hospitals NHS Foundation 23 
Trust, S10 2JF, UK 24 
9 Department of Imaging, St Bartholomew’s Hospital, Barts Health, London, EC1A 7BE, UK 25 
10 Department of Endocrinology and INSERM U862, University and CHU of Bordeaux, France 26 
11Internal Medicine 1, Department of Clinical and Biological Sciences, University of Turin, Italy 27 
12 Department of Endocrinology, Diabetes and Metabolism, Evangelismos Hospital, Athens, 28 
Greece 29 
13 Departments of Clinical Epidemiology and Internal Medicine, Leiden University Medical 30 
Centre, Leiden, The Netherlands 31 
14 Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.  32 
2 
ESE and ENSAT guideline on adrenal incidentaloma v.21.3.2016 
Abstract 33 
By definition, an adrenal incidentaloma is an asymptomatic adrenal mass detected on imaging 34 
not performed for suspected adrenal disease. In most cases, adrenal incidentalomas are non-35 
functioning adrenocortical adenomas, but may also represent conditions requiring therapeutic 36 
intervention including adrenocortical carcinoma, pheochromocytoma, hormone-producing 37 
adenoma or metastasis. The purpose of this guideline is to provide clinicians with best possible 38 
evidence-based recommendations for clinical management of patients with adrenal 39 
incidentalomas based on the GRADE (Grading of Recommendations Assessment, 40 
Development and Evaluation) system.  41 
We predefined four main clinical questions crucial for the management of adrenal 42 
incidentaloma patients, addressing these four with systematic literature searches: A) How to 43 
assess risk of malignancy?; B) How to define and manage low level autonomous cortisol 44 
secretion, the so-called “subclinical” Cushing syndrome?; C) Who should have surgical 45 
treatment and how should it be performed?; D) What follow-up is indicated if the adrenal 46 
incidentaloma is not surgically removed? 47 
Selected Recommendations: 1) At the time of initial detection of an adrenal mass 48 
establishing whether the mass is benign or malignant is an important aim to avoid cumbersome 49 
and expensive follow-up imaging in those with benign disease. 2) To exclude cortisol excess a 50 
1-mg overnight dexamethasone suppression test should be performed (applying a cutoff value 51 
of serum cortisol ≤ 50 nmol/l (1.8 µg/dl)). 3) For patients without clinical signs of overt Cushing's 52 
syndrome but serum cortisol levels post 1mg dexamethasone > 140 nmol/l (> 5 µg/dl) we 53 
propose the term ‘autonomous cortisol secretion’. 4) All patients with ‘(possible) autonomous 54 
cortisol’ secretion should be screened for hypertension and type 2 diabetes mellitus, to ensure 55 
these are appropriately treated. 5) Surgical treatment should be considered in an individualized 56 
approach in patients with 'autonomous cortisol secretion' who also have comorbidities that are 57 
potentially related to cortisol excess. 6) In principle, the appropriateness of surgical intervention 58 
should be guided by the likelihood of malignancy, the presence and degree of hormone excess, 59 
age, general health and patient preference. 7) Surgery is not usually indicated in patients with 60 
an asymptomatic, non-functioning unilateral adrenal mass and obvious benign features on 61 
imaging studies. We provide guidance on which surgical approach should be considered for 62 
adrenal masses with radiological findings suspicious of malignancy. Furthermore, we offer 63 
recommendations for the follow-up of patients with adrenal incidentaloma who do not undergo 64 
adrenal surgery, for those with bilateral incidentalomas, for patients with extra-adrenal 65 
malignancy and adrenal masses, and for young and elderly patients with adrenal 66 
incidentalomas. 67 
68 
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1. Summary of Recommendations* 69 
1.1  General remarks 70 
R.1.1  We recommend that patients with adrenal incidentalomas are discussed in a 71 
multidisciplinary expert team meeting, if at least one of the following criteria is met: 72 
- Imaging is not consistent with a benign lesion. 73 
- There is evidence of hormone excess (including “autonomous cortisol secretion”). 74 
- Evidence of significant tumor growth during follow-up imaging. 75 
- Adrenal surgery is considered. 76 
1.2  Assessment of the risk of malignancy 77 
R.2.1 We recommend aiming to establish if an adrenal mass is benign or malignant at the 78 
time of initial detection.  79 
R.2.2 We recommend that all adrenal incidentalomas undergo an imaging procedure to 80 
determine if the mass is homogeneous and lipid-rich and therefore benign (XOOO). For 81 
this purpose, we primarily recommend the use of non-contrast CT (XOOO).  82 
R.2.3 We suggest that if the non-contrast CT is consistent with a benign adrenal mass 83 
(Hounsfield units ≤ 10) that is homogeneous and smaller than 4 cm no further imaging is 84 
required (XOOO).  85 
R.2.4 If the adrenal mass is indeterminate on non-contrast CT and the results of the hormonal 86 
work-up do not indicate significant hormone excess, three options should be considered 87 
by a multidisciplinary team acknowledging the patient’s clinical context: immediate 88 
additional imaging with another modality, interval imaging in 6 to 12 months (non-89 
contrast CT or MRI), or surgery without further delay. 90 
R.2.5 We recommend against the use of an adrenal biopsy in the diagnostic work-up of 91 
patients with adrenal masses unless there is a history of extra-adrenal malignancy and 92 
additional criteria are fulfilled (see R6.3.5).  93 
1.3  Assessment for hormone excess  94 
R.3.1 We recommend that every patient with an adrenal incidentaloma should undergo careful 95 
assessment including clinical examination for symptoms and signs of adrenal hormone 96 
excess. 97 
R.3.2 We recommend that all patients with adrenal incidentalomas undergo a 1-mg overnight 98 
dexamethasone suppression test to exclude cortisol excess (XXOO). 99 
R.3.3 We suggest interpretation of the results of the 1-mg overnight dexamethasone test as a 100 
continuous rather than categorical (yes/no) variable (XOOO). However, we recommend 101 
                                                          
* The recommendations are worded as recommend (strong recommendation) and suggest (weak 
recommendation). The quality of evidence behind the recommendations is classified as low very low 
(⊕ΟΟΟ), low (⊕⊕ΟΟ), moderate (⊕⊕⊕Ο) and strong (⊕⊕⊕⊕). See further Section 3.4. 
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using serum cortisol levels post dexamethasone ≤ 50 nmol/l (≤ 1.8 µg/dl) as a diagnostic 102 
criterion for the exclusion of autonomous cortisol secretion (XXOO).  103 
R.3.4 We suggest that post dexamethasone serum cortisol levels between 51 and 140 nmol/l 104 
(1.9 - 5.0 µg/dl) should be considered as evidence of ‘possible autonomous cortisol 105 
secretion’ and cortisol levels post dexamethasone > 140 nmol/l (> 5.0 µg/dl) should be 106 
taken as evidence of ‘autonomous cortisol secretion’. Additional biochemical tests to 107 
confirm cortisol secretory autonomy and assess the degree of cortisol secretion might 108 
be required. However, for the clinical management the presence of potentially cortisol-109 
related comorbidities and age of the patient are of major importance. 110 
R.3.5 We recommend against considering ‘autonomous cortisol secretion’ as a condition with 111 
a high risk for the development of overt Cushing’s syndrome (XXOO). 112 
R.3.6 We recommend screening patients with ‘possible autonomous cortisol secretion’ or 113 
‘autonomous cortisol secretion’ for hypertension and type 2 diabetes mellitus (XOOO) 114 
and suggest offering appropriate treatment of these conditions. 115 
R.3.7 We suggest screening patients with ‘autonomous cortisol secretion’ for asymptomatic 116 
vertebral fractures (XOOO) and to consider appropriate treatment of these conditions 117 
(XOOO).  118 
R.3.8 We suggest an individualized approach to consider patients with ‘autonomous cortisol 119 
secretion’ due to a benign adrenal adenoma and comorbidities potentially related to 120 
cortisol excess for adrenal surgery (XOOO). Age, degree of cortisol excess, general 121 
health, comorbidities and patient’s preference should be taken into account. In all 122 
patients considered for surgery, ACTH-independency of cortisol excess should be 123 
confirmed.  124 
R.3.9 We recommend excluding pheochromocytoma by measurement of plasma free 125 
metanephrines or urinary fractionated metanephrines.  126 
R.3.10 In patients with concomitant hypertension or unexplained hypokalemia, we recommend 127 
the use of the aldosterone / renin ratio to exclude primary aldosteronism. 128 
R.3.11 We suggest measurement of sex hormones and steroid precursors in patients with 129 
clinical or imaging features suggestive of adrenocortical carcinoma. 130 
1.4  Surgical treatment  131 
R.4.1 We recommend adrenalectomy as the standard of care for unilateral adrenal tumors 132 
with clinically significant hormone excess.  133 
R.4.2 We recommend against performing surgery in patients with an asymptomatic, non-134 
functioning unilateral adrenal mass and obvious benign features on imaging studies 135 
(XOOO). 136 
R.4.3 We suggest performing laparoscopic adrenalectomy in patients with unilateral adrenal 137 
masses with radiological findings suspicious of malignancy and a diameter ≤ 6 cm, but 138 
without evidence of local invasion (XOOO). 139 
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R.4.4 We recommend performing open adrenalectomy for unilateral adrenal masses with 140 
radiological findings suspicious of malignancy and signs of local invasion (XOOO). 141 
R.4.5 We suggest an individualized approach in patients that do not fall in one of the above- 142 
mentioned categories (XOOO).  143 
R.4.6 We recommend perioperative glucocorticoid treatment at major surgical stress doses as 144 
recommended by guidelines, in all patients undergoing surgery for an adrenal tumor 145 
where there is evidence of ‘(possible) autonomous cortisol secretion’, i.e. who do not 146 
suppress to <50 nmol/L after 1mg dexamethasone overnight.  147 
1.5  Follow-up of patients not undergoing adrenal surgery after initial 148 
assessment 149 
R.5.1 We suggest against further imaging for follow-up in patients with an adrenal mass < 150 
4cm with clear benign features on imaging studies (XOOO).  151 
R.5.2 In patients with an indeterminate adrenal mass (by imaging) opting not to undergo 152 
adrenalectomy following initial assessment, we suggest a repeat non-contrast CT or 153 
MRI after 6-12 months to exclude significant growth (XOOO). We suggest surgical 154 
resection if the lesion enlarges by more than 20% (in addition to at least a 5 mm 155 
increase in maximum diameter) during this period. If there is growth of the lesion below 156 
this threshold, additional imaging after 6-12 months should be performed. 157 
R.5.3 We suggest against repeated hormonal work-up in patients with a normal hormonal 158 
work-up at initial evaluation unless new clinical signs of endocrine activity appear or 159 
there is worsening of comorbidities (e.g. hypertension and type 2 diabetes) (XOOO).  160 
R.5.4 In patients with ‘autonomous cortisol secretion’ without signs of overt Cushing’s 161 
syndrome, we suggest annual follow-up re-assessment for cortisol excess and careful 162 
assessment of comorbidities potentially related to cortisol excess (XOOO). Based on 163 
the outcome of this evaluation the potential benefit of surgery should be considered.  164 
1.6  Special circumstances 165 
1.6.1  Patients with bilateral adrenal incidentalomas 166 
R.6.1.1 We recommend that for patients with bilateral adrenal masses each adrenal lesion is 167 
assessed at the time of initial detection according to the same imaging protocol as for 168 
unilateral adrenal masses to establish if either or both masses are benign or 169 
malignant. 170 
R.6.1.2 We recommend that all patients with bilateral adrenal incidentalomas should undergo 171 
clinical and hormonal assessment identical to that in patients with unilateral adrenal 172 
incidentaloma. The same applies for the assessment of comorbidities that might be 173 
related to autonomous cortisol secretion. In addition, 17-hydroxyprogesterone should 174 
be measured to exclude congenital adrenal hyperplasia, and testing for adrenal 175 
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insufficiency should be considered, if suspected on clinical grounds or if imaging 176 
suggests bilateral infiltrative disease or hemorrhages. 177 
R.6.1.3 We suggest that for patients with bilateral incidentaloma the same recommendations 178 
regarding the indication for surgery and follow-up are used as for patients with 179 
unilateral adrenal incidentalomas.  180 
R.6.1.4 We suggest that in patients with bilateral adrenal masses bilateral adrenalectomy is 181 
not performed for ACTH-independent ‘autonomous cortisol secretion’ without clinical 182 
signs of overt Cushing’s syndrome. In selected patients, a unilateral adrenalectomy of 183 
the dominant lesion might be considered using an individualized approach considering 184 
age, degree of cortisol excess, general condition, comorbidities and patient 185 
preference. 186 
1.6.2  Adrenal incidentalomas in young or elderly patients 187 
R.6.2.1 We recommend urgent assessment of an adrenal mass in children, adolescents, 188 
pregnant women and adults < 40 years of age because of a higher likelihood of 189 
malignancy.  190 
R.6.2.2 We suggest the use of MRI rather than CT in children, adolescents, pregnant women 191 
and adults < 40 years of age if dedicated adrenal imaging is required. 192 
R.6.2.3 We recommend that the management of patients with poor general health and a high 193 
degree of frailty be kept in proportion to potential clinical gain. 194 
1.6.3 Patients with a newly diagnosed adrenal mass and a history of extra-195 
 adrenal malignancy 196 
R.6.3.1  We recommend measurement of plasma or urinary metanephrines to exclude 197 
pheochromocytoma in patients with extra-adrenal malignancy with an indeterminate 198 
mass, even if the adrenal mass is likely to be a metastasis. We suggest additional 199 
hormonal work-up based on an individualized approach.  200 
R.6.3.2 We suggest that in patients with a history of extra-adrenal malignancy FDG-PET/CT, 201 
performed as part of investigations for the underlying malignancy, can replace other 202 
adrenal imaging techniques.  203 
R.6.3.3 We recommend that in patients with a history of extra-adrenal malignancy adrenal 204 
lesions characterized as benign (see also R.2.3) by non-contrast CT require no further 205 
specific adrenal imaging follow-up. 206 
R.6.3.4 For indeterminate lesions in patients with a history of extra-adrenal malignancy, we 207 
recommend imaging follow-up assessing the potential growth of the lesion at the same 208 
interval as imaging for the primary malignancy. Alternatively, FDG-PET/CT, surgical 209 
resection or a biopsy (see also R.6.3.5) can be considered. 210 
R.6.3.5 We suggest performing a biopsy of an adrenal mass only if all of the following criteria 211 
are fulfilled: (i) the lesion is hormonally inactive (in particular, a pheochromocytoma 212 
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has been excluded), (ii) the lesion has not been conclusively characterized as benign 213 
by imaging, and (iii) management would be altered by knowledge of the histology.  214 
R.6.3.6 We recommend assessment of residual adrenal function in patients with large bilateral 215 
adrenal metastases.  216 
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2. Adrenal Incidentaloma – Clinical presentation and terminology  217 
2.1 Definition, etiology and epidemiology of adrenal incidentalomas 218 
An adrenal incidentaloma is an adrenal mass detected on imaging not performed for suspected 219 
adrenal disease. By this strict definition, the imaging study is not done for symptoms related to 220 
adrenal hormone excess (e.g. pheochromocytoma, Cushing’s or Conn’s syndrome) or an 221 
otherwise suspected adrenal mass, but rather for the evaluation of symptoms that are not 222 
obviously related to an adrenal problem, such as abdominal or back pain or kidney stones. 223 
Similarly, screening imaging in patients with a hereditary syndrome leading to adrenal tumors is 224 
outside the definition of an adrenal incidentaloma. In addition, adrenal masses discovered on 225 
an imaging study performed during tumor evaluation for extra-adrenal malignancies (“tumor 226 
staging” or follow-up) do not meet the strict definition of adrenal incidentaloma. However, as 227 
this is a clinically frequent scenario, we will address this in a specific chapter (see 5.6.4).  228 
Previous recommendations and reviews {Barzon, 1999 #112;Barzon, 2003 #38;Cawood, 2009 229 
#35;Favia, 2000 #114;Grumbach, 2003 #39;Kloos, 1995 #36;Mansmann, 2004 #40;Tabarin, 230 
2008 #59;Terzolo, 2011 #33;Young, 2007 #43;Zeiger, 2009 #57;Zeiger, 2009 #58;Young, 2000 231 
#147} have not considered adrenal incidentalomas smaller than 1 cm. Although this cut-off is 232 
obviously somewhat arbitrary, we agree with this approach and would perform additional 233 
diagnostic work-up only in lesions ≥ 1cm unless clinical signs and symptoms suggestive of 234 
adrenal hormone excess are present.  235 
The etiology of adrenal incidentalomas varies and includes benign and malignant lesions 236 
derived from the adrenal cortex, the medulla or of extra-adrenal origin. The reported frequency 237 
varies, depending on the context of the study and inclusion size criteria (see Table 1). Some 238 
authors conclude, however, that the prevalence of malignant and functional lesions is likely to 239 
be overestimated {Cawood, 2009 #35}, mainly because the prevalence of malignancy in 240 
surgical series is usually higher than in series including all patients presenting with an adrenal 241 
mass. There is, however, clear evidence that the vast majority of adrenal incidentalomas are 242 
benign adrenocortical adenomas.  243 
 244 
The incidence and prevalence of adrenal incidentalomas can only be extrapolated from imaging 245 
or autopsy studies. Autopsy studies suggest a prevalence of clinically unapparent adrenal 246 
masses of around 2% (range 1.0-8.7%), which increases with age {Kloos, 1995 247 
#36;Mansmann, 2004 #40;Grumbach, 2003 #39}. Radiological studies report a frequency of 248 
around 3% in the age of 50 years, which increases up to 10% in the elderly {Kloos, 1995 249 
#36;Mansmann, 2004 #40;Grumbach, 2003 #39;Barzon, 2003 #38;Mantero, 2000 #37;Bovio, 250 
2006 #45;Benitah, 2005 #44}. In childhood, adrenal incidentalomas are extremely rare.   251 
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Table 1: Adrenal incidentalomas - frequency of the different underlying tumor 252 
types (adapted according {Terzolo, 2011 #33}) 253 
 254 
Tumor entity Median (%) Range (%) 
Series including all patients with an adrenal mass*  
Adenoma 80 33-96 
Non-functioning 75 71-84 
Autonomously cortisol-secreting  12 1.0-29 
Aldosterone-secreting 2.5 1.6-3.3 
Pheochromocytoma 7.0 1.5-14 
Adrenocortical carcinoma 8.0 1.2-11 
Metastasis 5.0 0-18 
Surgical series**   
Adenoma 55 49-69 
Non-functioning 69 52-75 
Cortisol-secreting 10 1.0-15 
Aldosterone-secreting 6.0 2.0-7.0 
Pheochromocytoma 10 11-23 
Adrenocortical carcinoma 11 1.2-12 
Myelolipoma 8.0 7.0-15 
Cyst 5.0 4.0-22 
Ganglioneuroma 4.0 0-8.0 
Metastasis 7.0 0-21 
 255 
* Data from references: {Barzon, 2003 #38;Kloos, 1995 #36;Mantero, 2000 #37} 256 
** Data from references: {Barzon, 2003 #38;Kloos, 1995 #36;Mantero, 2000 #37;Bernini, 2002 257 
#41;Cawood, 2009 #35;Lam, 2002 #42;Mansmann, 2004 #40;Young, 2007 #43} 258 
Due to the nature of these studies a selection bias is very probable (the populations studied not reflecting 259 
a random sample of all patients with an adrenal incidentalomas) and most likely leads to an 260 
overestimation of the frequency of some tumor entities. 261 
 262 
2.2. Remarks on terminology  263 
As already discussed above, the term 'adrenal incidentaloma' can be defined by very restrictive 264 
criteria, but is sometimes used in a much broader sense, referring to any adrenal mass. 265 
Therefore, in the guideline we frequently speak of adrenal masses or lesions.  266 
Another term, which is widely used in the literature in the context of adrenal incidentaloma, is 267 
‘subclinical Cushing’s syndrome’ {Ross, 1994 #131}. This term aims to define patients with 268 
biochemical evidence of cortisol excess, but without the so-called "specific" clinical signs of 269 
Cushing’s syndrome (mainly the lack of catabolic features, like myopathy and skin fragility). 270 
There is, however, clear evidence that patients with clinically unapparent cortisol excess very 271 
rarely develop Cushing’s syndrome {Barzon, 1999 #112;Barzon, 2003 #38;Bernini, 2005 272 
#137;Fagour, 2009 #136;Libe, 2002 #123;Terzolo, 2005 #135;Terzolo, 1998 #134;Nieman, 273 
2015 #142} and that this condition is different from overt Cushing’s syndrome, which is clearly 274 
associated with severe morbidity and elevated mortality {Dekkers, 2013 #130;Lacroix, 2015 275 
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#140;Neychev, 2015 #141;Nieman, 2015 #139;Nieman, 2015 #138}. Nevertheless, there is 276 
some evidence that this low-grade autonomous cortisol excess might be associated with 277 
certain comorbidities (see Table 2). Thus, the panel unanimously decided to avoid the term 278 
“subclinical Cushing’s syndrome” and to use instead the term “‘autonomous cortisol secretion’” 279 
in the context of an adrenal incidentaloma throughout the guideline text (for the exact definition 280 
see chapter 5.3).  281 
Although the term “laparoscopic adrenalectomy” is actually reserved for operations that use a 282 
transperitoneal approach and should be distinguished from the term retroperitoneoscopic 283 
adrenalectomy, this never gained general acceptance. Therefore, in this guideline we use the 284 
term “laparoscopic adrenalectomy” to refer to minimally invasive approaches including 285 
retroperitoneoscopic surgery.  286 
 287 
Table 2: Comorbidities possibly associated with adrenal incidentalomas with 288 
‘autonomous cortisol secretion’  289 
Comorbidities Reference 
Hypertension {Terzolo, 2005 
#146;Terzolo, 2005 
#135;Tauchmanova, 
2002 #143;Emral, 2003 
#144;Bernini, 2003 
#164;Morelli, 2010 
#163;Rossi, 2000 
#162} 
Glucose intolerance / type 2 diabetes mellitus {Terzolo, 2005 
#146;Terzolo, 2005 
#135;Tauchmanova, 
2002 #143;Emral, 2003 
#144;Reincke, 1996 
#166;Bernini, 2003 
#164;Di Dalmazi, 2012 
#12;Fernandez-Real, 
1998 #165;Morelli, 
2010 #163;Rossi, 2000 
#162} 
Obesity {Terzolo, 2005 
#146;Terzolo, 2005 
#135;Tauchmanova, 
2002 #143;Emral, 2003 
#144} 
Dyslipidemia {Terzolo, 2005 
#146;Terzolo, 2005 
#135;Tauchmanova, 
2002 #143;Giordano, 
2010 #6;Rossi, 2000 
#162} 
Osteoporosis {Hadjidakis, 2003 
#145;Chiodini, 2004 
#18;Chiodini, 2009 
#53;Chiodini, 2010 
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#11;Eller-Vainicher, 
2012 #13;Morelli, 2011 
#14;Di Dalmazi, 2012 
#12;Morelli, 2010 #163} 
 290 
 291 
2.3. Short overview on adrenal imaging 292 
For the differentiation of malignant from benign adrenal tumors, there are three main imaging 293 
techniques in current use: computed tomography (CT), magnetic resonance imaging (MRI), 294 
and positron emission tomography with 18F-2-deoxy-D-glucose (mostly combined with CT; 295 
FDG-PET/CT). CT and MRI are techniques mainly aiming to identify benign lesions, therefore 296 
representing tools designed for the exclusion of adrenal malignancy {Peppercorn, 1998 297 
#168;Caoili, 2002 #80;Blake, 2006 #93;Ilias, 2007 #167}. Conversely, FDG-PET/CT is mainly 298 
used for the detection of malignant disease {Mackie, 2006 #185;Groussin, 2009 299 
#100;Deandreis, 2011 #184}. 300 
CT has a high spatial and quantitative contrast resolution, which allows assessment of tissue 301 
density by measuring X-ray absorption of tissues. This allows calculation of tissue attenuation 302 
or tissue density values, which are measured in Hounsfield units (HU) and quantify X-ray 303 
absorption of tissues compared to water, which is conventionally allocated a HU value of 0. For 304 
non-contrast (or ‘unenhanced’) CT, HU of ≤ 10 is the most widely used threshold attenuation 305 
value for the diagnosis of a lipid-rich, benign adrenal adenoma {Boland, 1998 #201}. However, 306 
on non-contrast CT, some 30% of benign adenomas have an attenuation value of > 10 HU and 307 
are considered lipid-poor, overlapping in density with malignant lesions and 308 
pheochromocytomas {Caoili, 2000 #202;Pena, 2000 #171;Zhang, 2012 #183}.  309 
Contrast-enhanced washout CT utilizes the unique perfusion pattern of adenomas. 310 
Adenomas take up intravenous CT contrast rapidly, but also have a rapid loss of contrast - a 311 
phenomenon termed ‘contrast enhancement washout’. It is assumed that malignant adrenal 312 
lesions usually enhance rapidly but demonstrate a slower washout of contrast medium. This 313 
washout phenomenon can be quantified by ‘contrast washout values’, which involve lesion 314 
attenuation measurements at specific time points acquired in a dedicated adrenal CT: prior to 315 
injection of contrast medium (HUnativ), at 60 seconds following injection of contrast medium 316 
(HUmax) and then at 10 or 15 minutes after contrast injection. This allows calculation of the 317 
relative contrast enhancement washout (=100x(HUmax-HU10/15min)/HUmax) and absolute contrast 318 
enhancement washout (=100x(HUmax-HU10/15min)/(HUmax-HUnativ)). A relative washout > 40% and 319 
an absolute washout > 60% is assumed to suggest that an adrenal lesion is benign {Pena, 320 
2000 #171;Dunnick, 2002 #205;Szolar, 1998 #174;Young, 2011 #182}. 321 
MRI is a non-ionising radiation based imaging modality utilizing weak radio wave signals 322 
emitted by body tissues when the body is placed in a strong magnetic field and radio frequency 323 
pulses are applied. The advantages of MRI over CT are its lack of radiation exposure, lack of 324 
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iodine-based contrast media and its superior tissue contrast resolution. For the differentiation of 325 
benign and malignant adrenal masses the MRI technique of chemical-shift imaging is most 326 
commonly used {McNicholas, 1995 #68;Sahdev, 2004 #175;Korobkin, 1996 #177;Korobkin, 327 
1996 #178;Haider, 2004 #181;Young, 2011 #182}. Chemical shift imaging relies on the fact 328 
that, within magnetic fields, protons in water vibrate at a slightly different frequency than 329 
protons in lipid. As a result, water and fat protons oscillate in and out of phase with respect to 330 
one another. By selecting appropriate sequencing parameters, separate images can be 331 
generated with water and fat protons oscillating in-phase or out-of-phase to each other. Adrenal 332 
adenomas with a high content of intracellular lipid usually lose signal intensity on out-of-phase 333 
images compared to in-phase images, whereas malignant lesions and pheochromocytomas 334 
(but also lipid-poor adrenal adenomas) that all lack intracellular lipid remain unchanged {Haider, 335 
2004 #181;Dunnick, 2002 #205;Bharwani, 2011 #212}. Simple visual assessment of signal 336 
intensity loss is diagnostic in most cases but quantitative methods may be useful in less clear 337 
cut cases. Quantitative analysis can be made using the adrenal-to-spleen signal ratio and the 338 
signal intensity index. MR signal intensity units are arbitrary units, unlike CT, and therefore are 339 
subject to numerous technical variations. 340 
18F-FDG-PET is a nuclear medicine modality that provides quantitative tomographic images 341 
after intravenous injection of a beta-radiation emitting radiotracer (18-Fluorine) used to label 2-342 
deoxy-D-glucose rendering Fluoro-deoxyglucose (18F-FDG). Both glucose and deoxyglucose 343 
enter cells via cell glucose transporters and undergo phosphorylation but while glucose 344 
undergoes further enzymatic breakdown, deoxyglucose becomes trapped in intracellular 345 
compartments. Cancer cells have an increased requirement for glucose and, therefore, take up 346 
more glucose and deoxyglucose than normal cells {Becherer, 2001 #188}. However, 18F-FDG 347 
is not a specific marker for cancer cells but a marker only for increased glucose metabolism 348 
thus uptake can also be increased in cells with an increased energy requirement due to 349 
conditions other than cancer. Quantitative measurement of 18F concentrations within tissues 350 
provides the most commonly used clinical measurement index, standard uptake value (SUV), 351 
which compares the intensity of uptake of 18F in the adrenal lesion to the average uptake of 352 
whole body. SUV values have been utilized to differentiate between benign from malignant 353 
adrenal lesions. FDG-PET has a high sensitivity for detection of metabolic changes but its 354 
spatial resolution for anatomical localization is poor. The solution is a hardware fusion between 355 
PET and CT (PET/CT) allowing simultaneous acquisition of PET and CT data. In clinical 356 
practice this involves injecting patients with 18F-FDG tracers at least one hour prior to the start 357 
of combined PET/CT. Once post processing is complete, PET and CT data can be viewed 358 
separately, side-by-side or as a fused images {Vogel, 2004 #214}.  359 
Other potentially emerging imaging techniques (e.g. metomidate-based adrenal imaging) are 360 
not yet clinically widely available and, therefore, will not be discussed in this guideline.  361 
 362 
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2.4. Remarks on the difficulties with hormonal testing 363 
Hormone assessment is crucial in the context of the work-up for an adrenal incidentaloma. 364 
However, there are several pitfalls that have to be considered (e.g. daily rhythm, sex-/ age-365 
dependency, limitations of assays, drug interactions). Furthermore, normal ranges vary 366 
substantially, depending on the method used, so it is essential to interpret test results in the 367 
context of the appropriate reference range. Due to space restrictions we refer to other 368 
guidelines that have addressed these issues in more detail {Nieman, 2008 #47;Lenders, 2014 369 
#48}.   370 
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3. Methods  371 
3.1. Guideline working group 372 
This guideline was developed by The European Society of Endocrinology (ESE) in 373 
collaboration with the European Network for the Study of Adrenal Tumours (ENSAT), supported 374 
by CBO (Dutch Institute for health care improvement). The chairs of the working group Martin 375 
Fassnacht (clinical) and Olaf Dekkers (methodology) were appointed by the ESE Clinical 376 
Committee. The other members were suggested by the chairs and approved by the Clinical 377 
Committee of ESE: endocrinologists (Wiebke Arlt (UK), Irina Bancos (USA), John Newell-Price 378 
(UK), Antoine Tabarin (France), Massimo Terzolo (Italy), Stylianos Tsagarakis (Greece), a 379 
radiologist (Anju Sahdev (UK), and an endocrine surgeon (Henning Dralle (Germany)). Irina 380 
Bancos served as representative of The Endocrine Society USA. The working group had three 381 
in-person meetings (December 2013, October 2014, and June 2015) and communicated by 382 
phone and email. Consensus was reached upon discussion; minority positions were taken into 383 
account in the rationale behind recommendations. Prior to the process, all participants 384 
completed conflict of interest forms. 385 
 386 
 387 
3.2 Target group  388 
This guideline was developed for healthcare providers of patients with adrenal incidentalomas 389 
ie, endocrinologists, radiologists, surgeons, and specialists in internal medicine. However, 390 
general practitioners might also find the guideline useful, as might our patients. In addition, the 391 
guideline document can serve as guidance for patient information leaflets. A draft of the 392 
guideline was reviewed by four experts in the field (see “Acknowledgment’ section) and has 393 
been submitted for comments by ESE and ENSAT members. All comments and suggestions 394 
were then discussed and implemented as appropriate by the panel.  395 
 396 
 397 
3.3 Aims  398 
The overall purpose of this guideline is to provide clinicians with practical guidance for the 399 
management of patients with adrenal incidentalomas.  400 
 401 
 402 
3.4 Summary of methods used for guideline development 403 
The methods used have been described in more detail previously {Bollerslev, 2015 #46}. In 404 
short, the guideline used GRADE (Grading of Recommendations Assessment, Development 405 
and Evaluation) as a methodological base. The first step was to define clinical question(s) (see 406 
section 3.5), the second being a systematic literature search (see Section 3.6). After including 407 
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relevant articles, we 1), estimated an average effect for specific outcomes (if possible), and 2), 408 
rated the quality of the evidence. The quality of evidence behind the recommendations is 409 
classified as very low (⊕ΟΟΟ), low (⊕⊕ΟΟ), moderate (⊕⊕⊕Ο) and strong (⊕⊕⊕⊕). Evidence 410 
tables are provided in Supplemental file II.  411 
For the recommendations we took into account: 1) quality of the evidence, 2) balance of 412 
desirable and undesirable outcomes, 3) values and preferences (patient preferences, goals for 413 
health, costs, management inconvenience, feasibility of implementation, etc). {Hammarstedt, 414 
2010 #126;Andrews, 2013 #133}. The recommendations are worded as recommend (strong 415 
recommendation) and suggest (weak recommendation). Formal evidence syntheses were 416 
performed and graded only for recommendations addressing our initial questions. Additional 417 
recommendations based on good practice were not graded {Ferreira, 2005 #128}. 418 
Recommendations were derived from majority consensus of the guideline development 419 
committee, but if members had substantive disagreements, this is acknowledged in the 420 
manuscript. For transparency, all recommendations provided are accompanied by text 421 
explaining why specific recommendations were made.  422 
 423 
 424 
3.5.   Clinical question, eligibility criteria and endpoint definition 425 
At the beginning of the guideline development process, the panel agreed on the four most 426 
important clinical questions in the management of patients with adrenal incidentalomas (Table 427 
3), for which a detailed literature search was subsequently performed.  428 
 429 
 430 
3.6 Description of search and selection of literature 431 
A literature search in electronic medical databases was performed for all four clinical questions 432 
separately. Of note, the approach for clinical question 1 (assessment of the risk of malignancy) 433 
differed as the search, study selection and also the evidence synthesis was performed in the 434 
context of a formal systematic review and meta-analysis published separately from the current 435 
guideline. For all four clinical questions details of the yield of the search are shown in Table 3. 436 
In summary, we included 37 studies for clinical question 1 (with 18 fulfilling the criteria for 437 
inclusion in the meta-analysis), twelve studies for clinical question 2a (biochemical profile in 438 
adrenal incidentaloma), four studies for clinical question 2b (therapeutic approach in mild 439 
glucocorticoid excess), nine studies for clinical question 3 (surgery) and ten studies plus one 440 
relevant systematic review for clinical question 4 (follow-up).  441 
 442 
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Table 3: Overview of the key clinical questions and predefined outcome parameters 443 
Clinical Question Predefined selection criteria and key outcome 
parameters1 
Metrics of the literature search 
Question 1a)  
What is the most accurate diagnostic imaging 
procedure to determine whether an adrenal 
mass is benign in patients with unilateral or 
bilateral adrenal mass(es) on imaging with or 
without history of other malignant lesions? 
• Original studies on imaging in patients with 
incidentally discovered adrenal mass(es), 
including those undergoing staging for known 
extra-adrenal malignancy. 
• Diagnostic intervention: CT (non-contrast, 
contrast-enhanced, washout), MRI, FDG 
PET(CT) 
• Reference standard: at least 50% of 
population had imaging-guided follow-up of 
any duration (for benign adrenal tumors), or 
histology after surgery or biopsy (for benign or 
malignant adrenal tumors) 
• Reporting 2x2 contingency table data or at 
least two indices of diagnostic accuracy 
(sensitivity, specificity, negative or positive 
predictive value) and disease prevalence.  
• 5496 abstracts2 
• 525 potentially relevant articles 
• 37 studies included in systematic 
review, 18 in meta-analysis 
• Major reasons for exclusion of 
articles were lack of test accuracy 
data, inadequate or unclear 
reference standard and ineligible 
populations. Other reasons for 
exclusion data collection pre-1990, 
sample size <10, < 50% histology 
in malignant group, >30% 
pheochromocytomas in malignant 
group, >10% pheochromocytomas 
in benign group, no differentiation 
of children versus adults 
Question 1b) 
What is the diagnostic accuracy of adrenal 
biopsy? 
• Original studies on patients with adrenal 
masses undergoing an adrenal biopsy 
procedure 
• Outcomes: non-diagnostic rate, diagnostic 
accuracy data, complication rate 
• For studies included in the diagnostic 
accuracy analysis: 1) Reference standard: at 
least 50% of population either histology from 
adrenalectomy or autopsy, imaging follow up 
3-12 months or clinical follow up of 2 years 
and 2) Reporting 2x2 contingency table data 
or at least two indices of diagnostic accuracy 
(sensitivity, specificity, negative or positive 
predictive value) and disease prevalence.  
 
• 175 abstracts3 
• 80 potentially relevant articles 
• 32 studies included in systematic 
review of at least one outcome.  
• Diagnostic accuracy data included 
from 8 studies 
• Major reasons for exclusion 
overall were: no outcomes of 
interest, fewer than 10 patients, 
abstract only, patient overlap. 
• Major exclusions from diagnostic 
accuracy analysis were: 
suboptimal reference standard 
and >30% non-adenomas 
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Question 2a)  
Are certain biochemical profiles (see 4.2.1) 
associated with an increased cardiovascular, 
metabolic and fracture risk in patients with 
adrenal mass(es), in whom endocrine work-
up for glucocorticoid excess was performed?  
Question 2b)  
Should surgery or a conservative/medical 
approach be recommended in patients with 
adrenal mass(es) and with defined 
biochemistry and cardiovascular, metabolic 
and fracture risk potentially indicative of mild 
glucocorticoid excess? 
• Original studies on patients with adrenal 
mass(es), in which endocrine work-up for 
glucocorticoid excess was performed. Studies 
independently of their respective definition of 
‘autonomous cortisol secretion’ were eligible. 
• Comparison between patients based on 
biochemical profiles (including post-
dexamethasone serum cortisol level) 
(question 2a)  
• Comparison between surgery and 
conservative approach (question 2b) 
• Reporting at least one of the crucial outcome: 
major cardiovascular events or mortality, 
vertebral fractures, metabolic profile, 
cardiovascular profile 
Question 2a:  
• 201 abstracts 
• 23 potentially relevant articles 
• 12 studies included 
Question 2b 
• 152 abstracts 
• 18 potentially relevant articles 
• 4 studies included 
• Excluded articles were not 
relevant for outcome parameters 
(n=17), no relevant design (n=4), 
overlapping populations (n=2), 
position paper (n=1), poorly 
defined patient cohort (n=1) 
Question 3)  
Should laparoscopic (=minimally-invasive) or 
open surgery be used for patients with non-
metastastic adrenal masses suspected to be 
malignant?  
• Original studies on adults with suspected non-
metastatic adrenocortical carcinoma 
• Comparison between laparoscopic versus 
open surgery 
• Reporting at least one of the crucial 
outcomes: perioperative morbidity and 
mortality; completeness of resection; 
recurrence-free and overall survival; pain or 
patient satisfaction 
• Publications with less than 10 patients per 
study arm were excluded.  
 
• 377 abstracts 
• 13 potentially relevant articles 
• 3 excluded due to samples size < 
10 patients per arm, 1 excluded as 
review 
• 9 studies included 
Question 4)  
What is the optimal follow-up in patients with 
an apparently benign adrenal incidentaloma 
in order to detect malignant transformation 
and/or development of overt hormone 
excess? 
 
• Original studies on patients with an adrenal 
mass without hormone excess and no clear 
evidence of malignant adrenal tumor at time of 
primary diagnosis 
• Reporting at least one of the following 
outcomes: malignancy in the adrenal (any 
kind); development of clinically relevant overt 
hormone excess (Cushing’s syndrome, 
• 133 abstracts 
• 19 potentially relevant articles 
• 9 excluded due to overlapping 
population (n=3), not relevant to 
question (n=3), not available in 
full-text (n=2), unclear methods 
(n=1) 
• Included: 
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pheochromocytoma, primary 
hyperaldosteronism) 
• 1 systematic review of 14 studies  
• 10 additional cohort studies 
   
 444 
1 For each question we searched separately for systematic reviews between 2000 and February 2014 in NHS Economic Evaluation Database (NHSEED), 445 
Cochrane Database of Systematic Reviews, and Database of Abstracts of Reviews of Effects. This revealed no relevant systematic review. Then, we 446 
searched for original articles in Medline published between 2000 and July 2014 (Question 3), October 2014 (Question 4), November 2014 (Question 2), and 447 
August 2015 (Question 1). 448 
2 Summary of separately published meta-analysis {Dinnes, 2016 #246}.  449 
3 Summary of separately published meta-analysis {Tamhane, 2016 #248} 450 
 451 
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4. Summary and conclusions from systematic literature reviews 452 
 453 
4.1  Assessment of the risk of malignancy (Question 1) 454 
4.1.1  Assessment of the risk of malignancy by imaging (Question 1a) 455 
The following paragraph represents a summary of a recent meta-analysis on the use of 456 
imaging for differentiating benign from malignant adrenal incidentalomas carried out with 457 
involvement of some of the guideline panel members {Dinnes, 2016 #246}. Studies were 458 
considered all studies of CT, MRI or FDG-PET in adults eligible if: 1) included patients 459 
underwent imaging for any indications other than investigation of suspected adrenal mass; 2) 460 
index imaging test characteristics were reported; 3) at least 50% of patients had an optimal 461 
reference standard: histological diagnosis in malignant masses and availability of histology or 462 
imaging follow up of any duration in the case of benign adrenal masses. Exclusion criteria 463 
are summarized in Table 3. The review looked separately at patients with true adrenal 464 
incidentaloma and patients with adrenal mass and a history of extra-adrenal malignancy. 465 
We identified 37 studies for inclusion in the systematic review {Angelelli, 2013 #218;Marin, 466 
2012 #224;Maurea, 2004 #88;Nunes, 2010 #101;Sandrasegaran, 2011 #105;Tessonnier, 467 
2008 #97;Vilar, 2008 #98;Burt, 1994 #63;Choi, 2013 #109;Frilling, 2004 #87;Lang, 2015 468 
#120;McNicholas, 1995 #68;Porte, 1999 #76;Ream, 2015 #111;Schwartz, 1995 469 
#69;Uemura, 2013 #111;Kunikowska, 2014 #121;Villar Del Moral, 2010 #104;Aksakal, 2013 470 
#108;Bilbey, 1995 #131;Blake, 2006 #93;Boraschi, 1999 #74;Chung, 2001 #77;Groussin, 471 
2009 #100;Gust, 2012 #106;Ichikawa, 1993 #61;Kamiyama, 2009 #219;Kebapci, 2003 472 
#84;Launay, 2015 #226;Mayo-Smith, 1995 #67;Nwariaku, 2001 #79;Park, 2015 #115;Park, 473 
2007 #96;Petersenn, 2015 #220;Remer, 2006 #94;Zettinig, 2004 #90;Zielonko, 2008 #99}, 474 
with only 18 of them fulfilling the criteria for inclusion in the actual meta-analysis {Angelelli, 475 
2013 #218;Marin, 2012 #224;Maurea, 2004 #88;Nunes, 2010 #101;Sandrasegaran, 2011 476 
#105;Tessonnier, 2008 #97;Vilar, 2008 #98;Burt, 1994 #63;Choi, 2013 #109;Frilling, 2004 477 
#87;Lang, 2015 #120;McNicholas, 1995 #68;Porte, 1999 #76;Ream, 2015 #111;Schwartz, 478 
1995 #69;Uemura, 2013 #111;Kunikowska, 2014 #121;Villar Del Moral, 2010 #104}. No 479 
randomized studies comparing imaging tests were identified. Risk of bias ranged from low to 480 
high, with the majority having unclear or high risk of bias (mainly due to unclear population 481 
selection, retrospective selection of the diagnostic threshold and inadequate reference 482 
standards with resulting concerns of the applicability of results). 483 
Five commonly used diagnostic thresholds were studied: (1) tumor density >10HU on non-484 
contrast CT; (2) CT with delayed contrast media washout: absolute percentage washout 485 
and/or relative percentage washout at any washout percentage % or delay time on enhanced 486 
CT; (3) MRI chemical shift analysis: loss of signal intensity between in and out of phase 487 
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images (including both qualitative and quantitative estimates of signal loss); and, for FDG-488 
PET or PET-CT, (4) the maximum standardized uptake value (SUVmax), and (5) the ratio of 489 
SUVmax in the adrenal gland compared to the liver (adrenal liver ratio).  490 
The 37 studies included were generally small with a median sample size of 45 (range 12 to 491 
181). Of the 18 studies included in the formal meta-analysis, 7 addressed purely incidental 492 
adrenal masses and 11 studies focused on patients with known extra-adrenal malignancy. 493 
Limited data (two studies with 102 true incidentalomas) suggest that CT density >10 HU has 494 
a high sensitivity for detection of adrenal malignancy (100%, 95% confidence interval 91-495 
100%); meaning that adrenal masses with a density of ≤10 HU are unlikely to be malignant. 496 
In patients with a history of extra-adrenal malignancy five studies evaluating the >10 HU cut-497 
off as indicative of malignancy showed high sensitivity (93%) for detection of malignancy but 498 
variable specificity; this means that 7% of adrenal metastases were found to have a tumor 499 
density of ≤10 HU.  500 
Disappointingly, all other estimates of test performance are based on small numbers of 501 
studies with very few patients and accompanying wide 95% confidence intervals, indicating 502 
much uncertainty in test performance for all other imaging markers. For true adrenal 503 
incidentalomas, two of three MRI studies reported slightly lower sensitivity and specificity 504 
than CT for measures of adrenal-liver and adrenal-spleen ratios and loss of signal intensity. 505 
The performance of PET for adrenal liver ratio and SUVmax measures in the two included 506 
studies was not clearly better than CT. In patients with a history of extra-adrenal malignancy, 507 
only one study reported on CT contrast-enhanced washout tests, which showed very low 508 
sensitivity (16%). Four of the five studies of MRI used 1.5 Tesla machines and reported high 509 
sensitivity (89%-99%) for measures of adrenal-liver, adrenal-spleen, adrenal-muscle ratios 510 
and loss of signal intensity. Specificity varied (60%-93%) but was high for most MRI 511 
measures. The performance of PET was similar to MRI for ALR and max SUV measures. 512 
Although more studies had evaluated CT, MRI and PET in the pathway for follow-up of 513 
known extra-adrenal malignancy than for incidentally discovered adrenal lesions, estimates 514 
of test performance are still based on too small numbers of studies to be able to discern 515 
whether any test performs adequately or better than alternative tests from the available data. 516 
 517 
4.1.2  Value of an adrenal biopsy (Question 1b) 518 
The following paragraph represents a summary of a recent systematic review carried out with 519 
involvement of some of the guideline panel members on published experience with adrenal 520 
biopsy and its outcomes {Tamhane, 2016 #248}. Inclusion criteria and definition of reference 521 
standard differed from the imaging meta-analysis mainly in population selection criteria (as 522 
adrenal biopsy is not indicated in incidentaloma population but rather in patients at high risk 523 
for malignancy) and in reference standard (where we accepted imaging and clinical follow up 524 
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in addition to histopathology as most metastases would not undergo adrenalectomy). We 525 
identified 32 studies {Deville, 2002 #13484;Macaskill P,  #13485;Moher, 2009 526 
#13486;Silverman, 1993 #237;Puri, 2015 #13487;Martinez, 2014 #13488;Welch, 1994 527 
#240;Rana, 2012 #13489;Mody, 1995 #172;Hussain, 1996 #13490;Wu, 1998 #72;Schwartz, 528 
1998 #73;Porte, 1999 #76;de Agustin, 1999 #67;Lumachi, 2001 #231;Lumachi, 2003 529 
#85;Paulsen, 2004 #230;Kocijancic, 2004 #13493;Lucchi, 2005 #13494;Lumachi, 2007 530 
#95;Quayle, 2007 #236;Tsitouridis, 2008 #142;Osman, 2010 #13496;Mazzaglia, 2009 531 
#13451;Bodtger, 2009 #13497;Eloubeidi, 2010 #13498;Schuurbiers, 2011 #13499;Tyng, 532 
2012 #13500;Tirabassi, 2012 #14;Rana, 2012 #13489;Martinez, 2014 #13390;Puri, 2015 533 
#13487} with a total of 2174 patients which reported at least one outcome of interest 534 
(complication rate, non-diagnostic rate, diagnostic accuracy parameters). Of these, only 8 535 
studies{Porte, 1999 #76;Lumachi, 2001 #231;Lumachi, 2003 #85;Lucchi, 2005 536 
#13494;Lumachi, 2007 #95;Quayle, 2007 #236;Tsitouridis, 2008 #142;Tirabassi, 2012 #14} 537 
were included for the diagnostic accuracy analysis, reasons for exclusion being lack of any or 538 
optimal reference standard for at least 50% patients (n=20) and more than 30% patients with 539 
non-adenomas in benign cohort (n=4). Included studies were assessed to be at a moderate 540 
risk for bias, most limitations relating to patient selection, assessment of outcome and 541 
adequacy of follow up of the study population.  542 
Studies had diverse population inclusion criteria, reference standards and biopsy techniques. 543 
Pathology of adrenal lesion was reported only for 1600/2207 cases. Out of these 819 were 544 
malignant (703 metastases, 67 ACCs, 49 other malignancies or not specified), 690 were 545 
benign and 91 were various other non-malignant lesions (36 pheochromocytomas, 29 546 
granulomas, 16 other). Pooled non-diagnostic rate derived from 30 studies (2030 adrenal 547 
biopsy procedures) was 8.6% (CI 6.1%-11%; I2 = 84%, p<0.001). Pooled overall 548 
complication rate derived from studies (1356 biopsies) was 2.4% (CI 1.5%-3.3%; I2 = 21%, 549 
p=0.175), though likely under-represented due to differences in both assessment and 550 
reporting of complication as well as retrospective nature of the studies. The diagnostic 551 
performance of adrenal biopsy was calculated using the data from the 8 studies (323 adrenal 552 
biopsy procedures) meeting pre-established eligibility criteria. Performance of adrenal biopsy 553 
in the diagnosis of malignancy overall was: sensitivity 87% (CI95% of 78-93%), specificity 554 
100% (CI95% of 76-100%), positive likelihood ratio of 229 (CI95% of 2.9-18145) and 555 
negative likelihood ratio of 0.13 (CI95% of 0.07-0.23). Performance was lower (and with even 556 
wide 95%CIs) for ACC: sensitivity 70% (CI95% of 42-88%), specificity 98% (CI95% of 86-557 
100%), positive likelihood ratio of 100.43 (CI95% of 8-1245) and negative likelihood ratio of 558 
30.9 (CI95% of 4.16-229). 559 
 560 
 561 
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4.2 Assessment of autonomous cortisol secretion in adrenal incidentalomas  562 
4.2.1 Assessment of autonomous cortisol secretion in relation to clinical outcomes 563 
(Question 2a, Appendices I and II) 564 
Studies were eligible for inclusion independent of the criteria used to define autonomous 565 
cortisol secretion. Three different hormonal profiles were distinguished to describe 566 
autonomous cortisol secretion associated with adrenal adenomas; Profile 1: serum cortisol > 567 
50 nmol/l (>1.8 µg/dl) after 1-mg, 2-mg, or 8-mg overnight dexamethasone suppression 568 
tests, or 2-day low dose dexamethasone test, and one of the following additional endocrine 569 
alterations: increased 24-h urinary free cortisol (UFC), low plasma ACTH, elevated midnight 570 
serum or salivary cortisol; Profile 2: serum cortisol > 83nmol/l (>3.0 µg/dl) after 1-mg 571 
overnight dexamethasone test and one additional endocrine alteration (same as above); 572 
Profile 3: cortisol > 140 nmol/l (>5 µg/dl) after 1-mg overnight dexamethasone test as sole 573 
criterion. The defined profiles do not fit completely with the specific criteria used in all of the 574 
studies included. Virtually all diagnostic algorithms are, however, variations of these profiles.  575 
 576 
In total, twelve studies were included: seven cross-sectional studies {Chiodini, 2004 577 
#18;Chiodini, 2009 #53;Di Dalmazi, 2012 #12;Eller-Vainicher, 2012 #13;Androulakis, 2014 578 
#17;Olsen, 2012 #15;Vassilatou, 2014 #243} and five cohort studies {Debono, 2014 #19;Di 579 
Dalmazi, 2014 #20;Giordano, 2010 #6;Morelli, 2011 #14;Morelli, 2014 #8}. In eight studies, a 580 
comparison was made between patients with elevated (group 1) or normal (group 2) cortisol 581 
levels after a 1-mg dexamethasone test. Two studies used the biochemical profile 1 and four 582 
studies used the biochemical profile 2 with a variation since the post-dexamethasone serum 583 
cortisol cutoff was not a mandatory criterion. Three studies identified 3 subgroups of patients 584 
{Debono, 2014 #19;Di Dalmazi, 2014 #20;Di Dalmazi, 2012 #12}, normal, intermediate and 585 
frankly altered cortisol suppression corresponding to cortisol levels after 1-mg 586 
dexamethasone of < 50 nmol/l (< 1.8 µg/dl), between 50 to 140 nmol/l (1.8 µg/dl - 5.0 µg/dl), 587 
and > 140 nmol/l (> 5.0 µg/dl), respectively.  588 
In the cross-sectional studies, the risk of bias is estimated as high, given the inability to 589 
assess causality and the potential for residual confounding factors, and these issues hamper 590 
the ability to make firm conclusions from these studies. Differences in diagnostic protocols, 591 
definitions of outcome, and duration of follow-up were associated with considerable 592 
heterogeneity between and within studies.  593 
 594 
Outcome measures 595 
Change in biochemical profile 596 
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In three studies with a median follow-up of 3, 6.9, and 7.5 years no patient progressed to 597 
overt Cushing’s syndrome during follow-up {Di Dalmazi, 2014 #20;Giordano, 2010 #6;Morelli, 598 
2014 #8}.  599 
 600 
Change in metabolic and cardiovascular profile 601 
The risk of type 2 diabetes was higher in patients with impaired cortisol suppression after 1-602 
mg dexamethasone test and increased further during follow-up {Di Dalmazi, 2014 #20;Di 603 
Dalmazi, 2012 #12;Morelli, 2014 #8}. Also, the risk of hypertension was higher in patients 604 
with impaired cortisol suppression and increased further with follow-up {Di Dalmazi, 2012 605 
#12;Morelli, 2014 #8;Olsen, 2012 #15;Vassilatou, 2009 #10}. A smaller study did not confirm 606 
the increase in diabetes and hypertension with time {Giordano, 2010 #6}.  607 
 608 
Major cardiovascular incidents  609 
In two cohort studies {Di Dalmazi, 2014 #20;Morelli, 2014 #8}, the incidence of 610 
cardiovascular events was higher in patients with altered cortisol suppression. 611 
 612 
Mortality 613 
Two studies reported on mortality {Debono, 2014 #19;Di Dalmazi, 2014 #20} and found an 614 
increased mortality risk in patients with higher cortisol levels after 1-mg dexamethasone. 615 
However, the results were adjusted for other prognostic factors only in the first study, and 616 
effect estimates were uncertain due to low number of events.  617 
 618 
Risk of vertebral fractures  619 
Four studies reported a higher prevalence of vertebral fractures {Chiodini, 2004 #18;Chiodini, 620 
2009 #53;Di Dalmazi, 2012 #12;Eller-Vainicher, 2012 #13} in patients with impaired cortisol 621 
suppression. In a cohort study {Morelli, 2011 #14}, the incidence of new vertebral fractures 622 
was higher in patients with impaired cortisol suppression. However, most of the detected 623 
vertebral fractures were minor and of uncertain clinical impact.  624 
 625 
 626 
4.2.2. Surgery vs. conservative management in patients with autonomous cortisol 627 
secretion (Question 2b, Appendices III and IV) 628 
For question 2b, four studies were included in which surgery was compared to a 629 
conservative approach: one randomized controlled trial and three observational studies. The 630 
randomized trial {Toniato, 2009 #22} reported on patients with autonomous cortisol secretion 631 
who underwent surgery (n=23) or were treated by a conservative approach (n=22). The 632 
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mean follow up was 7.7 years and the results were only a qualitative description of changes 633 
in hypertension, diabetes mellitus or dyslipidemia.  634 
Tsuiki et al. included patients with autonomous cortisol secretion and compared a group 635 
treated by surgery (n=10) and a group treated conservatively (n=10) {Tsuiki, 2008 #23}. 636 
Follow up was 7-19 months. The second cohort study included 41 patients with autonomous 637 
cortisol secretion (25 treated by surgery and 16 conservatively treated) {Chiodini, 2010 #11}. 638 
Outcome measures included: proportion of patients with steady, improved, or worsened 639 
blood pressure, fasting glucose or LDL cholesterol. In the third study by Iacobone et al, 372 640 
patients with autonomous cortisol secretion (20 treated by surgery and 15 conservatively 641 
treated) {Iacobone, 2012 #244}. Outcomes were blood pressure, glucose and cholesterol.  642 
The quality of evidence from these studies is low to very low, mainly due to confounding 643 
factors. Only one study was randomized, and none of the studies reported blinded outcome 644 
assessment. Most studies were also downgraded for imprecision, due to low number of 645 
events. Differences in diagnostic protocols, definitions of outcome, and duration of follow-up 646 
were associated with considerable heterogeneity between and within studies.  647 
 648 
 649 
Outcome measures 650 
 651 
Change in metabolic and cardiovascular profile in patients with autonomous cortisol 652 
secretion 653 
In the randomized trial, 25% of patients with type 2 diabetes mellitus had normalized 654 
glycemic control after surgery {Toniato, 2009 #22}, compared to none in the conservative 655 
group. The cohort studies {Chiodini, 2010 #11;Tsuiki, 2008 #23;Iacobone, 2012 #244} 656 
reported an improvement in glucose levels in 10-48% of patients after surgery. In the 657 
conservatively treated groups, none of the patients improved.  658 
The cohort studies {Chiodini, 2010 #11;Tsuiki, 2008 #23;Iacobone, 2012 #244} reported an 659 
improvement in hypertension and dyslipidemia in some patients after surgery. In the 660 
conservatively managed group, none of the patients improved.  661 
 662 
Risk of vertebral fractures 663 
None of the included studies reported on the risk of vertebral fractures.  664 
 665 
Major cardiovascular incidents and mortality  666 
None of the included studies reported on the risk of major cardiovascular events or mortality. 667 
 668 
 669 
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4.3  Surgical approach: open vs. minimally-invasive adrenalectomy (Question 3, 670 
Appendices V and VI) 671 
As adrenocortical carcinoma is the main threat for an adverse outcome in patients with 672 
adrenal incidentaloma undergoing surgery, we focused our efforts with regards to surgery on 673 
the management of adrenocortical carcinoma. Nine cohort studies on the surgical treatment 674 
of patients with non-metastatic adrenocortical carcinoma were included {Brix, 2010 675 
#24;Cooper, 2013 #25;Donatini, 2014 #26;Fossa, 2013 #27;Lombardi, 2012 #28;Miller, 2010 676 
#29;Miller, 2012 #30;Mir, 2013 #31;Porpiglia, 2010 #32}. Three studies reported on the 677 
patients in whom complete resection of the tumor was achieved {Donatini, 2014 678 
#26;Lombardi, 2012 #28;Porpiglia, 2010 #32}.  679 
 680 
The quality of evidence from these observational studies is very low, mainly because patient 681 
groups were not comparable at baseline with regard to important prognostic characteristics, 682 
such tumor stage or size. Tumor stage was, on average, lower in patients with laparoscopic 683 
surgery as compared to open surgery. In few studies {Brix, 2010 #24;Mir, 2013 #31}, 684 
treatment effects were adjusted for differences in tumor stage. Mostly, however, only 685 
uncorrected estimates of recurrence-free and overall survival were reported. Moreover, most 686 
studies had imprecise effect estimates. 687 
 688 
Outcome measures 689 
Perioperative mortality and morbidity  690 
One study reported on perioperative mortality {Brix, 2010 #24}. In this study, none of the 152 691 
patients died perioperatively. Three studies reported on intraoperative or postoperative 692 
complications {Fossa, 2013 #27;Lombardi, 2012 #28;Mir, 2013 #31}. Major postoperative 693 
complications (Clavien-classification score 3-5) occurred more often in open surgeries 694 
compared to laparoscopic surgeries (RR 1.7, 95% CI 0.5-6.2) but these estimates are 695 
imprecise due to low numbers of events.  696 
 697 
 698 
Completeness of resection 699 
In five studies the completeness of resection was reported {Brix, 2010 #24;Cooper, 2013 700 
#25;Fossa, 2013 #27;Miller, 2010 #29;Mir, 2013 #31}. The pooled estimate of these five 701 
studies indicated no clear difference in complete resection between surgical approaches (RR 702 
0.8 (95% CI 0.6 to 1.1)). The results of these studies were inconsistent, leading to much 703 
uncertainty regarding this conclusion.  704 
 705 
Recurrence-free and overall survival 706 
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Eight studies reported on recurrence after surgery, but differed in the presentation of these 707 
data. These studies also provided data on overall or disease-specific survival {Brix, 2010 708 
#24;Cooper, 2013 #25;Donatini, 2014 #26;Fossa, 2013 #27;Lombardi, 2012 #28;Miller, 2012 709 
#30;Mir, 2013 #31;Porpiglia, 2010 #32}. There is no compelling evidence that one of the 710 
approaches (laparoscopic or open adrenalectomy) is superior with regard to time to 711 
recurrence and/or survival in patients with adrenocortical carcinoma, provided that rupture of 712 
tumor capsule is excluded. However, the studies have significant limitations, inconsistencies 713 
and imprecision precluding reliance on this conclusion.  714 
 715 
Pain / patient satisfaction 716 
None of the studies reported on pain or patient satisfaction. 717 
 718 
4.4  Natural course of apparently benign adrenal incidentaloma (risk of malignancy 719 
or development of hormone excess) (Question 4, Appendix VII and VIII)  720 
A systematic review of fourteen studies assessing the natural course of 1410 patients with 721 
apparently benign, non-functioning adrenal incidentalomas {Cawood, 2009 #35} and ten 722 
additional cohort studies were included {Chiodini, 2010 #11;Cho, 2013 #3;Comlekci, 2010 723 
#4;Debono, 2013 #117;Fagour, 2009 #5;Giordano, 2010 #6;Kim, 2005 #7;Morelli, 2011 724 
#14;Morelli, 2014 #8;Muth, 2011 #9;Muth, 2013 #119;Song, 2008 #262;Vassilatou, 2009 725 
#10;Yener, 2009 #121}. The systematic review included studies reporting the follow up of 726 
adrenal incidentaloma patients, published between 1980 and 2008, including publications 727 
that reported more than 20 patients, and in which the majority were referred to an 728 
endocrinologist (excluding oncology series). The additional ten studies, published between 729 
2005 and 2014, included 1131 incidentaloma patients with apparently benign non-functioning 730 
tumors or with autonomous cortisol secretion.  731 
 732 
The quality of evidence from these studies was judged moderate or low. Selection criteria 733 
were often not reported, the duration of follow-up was heterogeneous across studies 734 
(medians ranging from 19 to 90 months) and the completeness of follow-up was difficult to 735 
assess. Information on the protocol of biochemical or radiological re-evaluation was not 736 
always provided and standardized. In addition, criteria for hormonal excess were 737 
heterogeneous across studies.  738 
 739 
Outcome measures 740 
Malignancy 741 
The estimated pooled risk for developing malignancy in the systematic review was 0.2% 742 
(95%CI 0.0 to 0.4) {Cawood, 2009 #35}. In two cohort studies, one case of malignancy was 743 
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found: one patient with adrenal non-Hodgkin lymphoma and one patient with renal cancer 744 
metastasis. In the first case, the imaging characteristics of the adrenal incidentaloma at the 745 
first evaluation were not consistent with benign characteristics and the lymphoma may have 746 
been misdiagnosed initially {Libe, 2002 #123}. The second case had a history of renal cell 747 
carcinoma and it is unclear whether the adrenal mass was found incidentally or during the 748 
follow-up for cancer {Tsvetov, 2007 #122}. No case of malignancy was reported in the other 749 
904 patients included in the cohort studies. Importantly, no malignant transformation of a 750 
presumably benign incidentaloma was reported.  751 
 752 
Development of clinically overt hormone excess 753 
The risk of developing overt Cushing’ syndrome in patients without clinical signs of Cushing's 754 
syndrome at the time of initial assessment ranged in the individual studies from 0% to 4%, 755 
whereas the risk of developing autonomous cortisol secretion in the absence of clinically 756 
overt Cushing’s syndrome was low, with a pooled estimate form a systematic review of 0.3% 757 
{Cawood, 2009 #35}. The risk of developing an aldosterone-producing adenoma in the 758 
individual studies ranged from 0% to 2%.The risk of developing a pheochromocytoma ranged 759 
from 0% to 2% but it is unclear whether an accurate initial imaging and biochemical 760 
screening was performed.  761 
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5.   Recommendations, Rationale for the Recommendations 762 
5.1. General remarks 763 
The main part of this guideline addresses the management of patients who fulfill the 764 
definition of adrenal incidentaloma (section 2.1). In addition, we discuss specific situations 765 
separately: bilateral adrenal masses (5.6.1), patients who are young or elderly and frail 766 
(5.6.2), and adrenal masses detected during evaluation for extra-adrenal malignancy (5.6.3).  767 
 768 
R.1.1  We recommend that patients with adrenal incidentalomas are discussed in a 769 
multidisciplinary expert team meeting, if at least one of the following criteria is 770 
met (Figure 1): 771 
- Imaging is not consistent with a benign lesion. 772 
- There is evidence of hormone excess (including ‘autonomous cortisol 773 
secretion’). 774 
- Evidence of significant tumor growth during follow-up imaging. 775 
- Adrenal surgery is considered.  776 
 777 
Reasoning:  778 
Although we believe that the ideal would be for all patients with adrenal incidentalomas to be 779 
managed by an expert multidisciplinary team, in many health care settings this is an 780 
unrealistic aspiration. Despite lack of compelling evidence, we aimed at identifying 781 
subgroups of patients that would be most likely to benefit from multidisciplinary team 782 
discussion, and that these discussions occur quickly for patients that meet the criteria above. 783 
The core multidisciplinary team should consist of at least a radiologist, an endocrinologist, 784 
and a surgeon, all with significant experience in adrenal tumors. Furthermore, this team 785 
should have access to anesthetists and an endocrine pathologist, who are experienced in 786 
adrenal tumors. Although it is beyond the scope of this guideline, the use of a standardized 787 
pathology report is highly recommended.  788 
There is sufficient evidence that higher surgical volume correlates with better outcome, 789 
however, for the time being no specific numbers of operations per year that result in this 790 
favorable outcome can be recommended {Park, 2009 #50;Kerkhofs, 2013 #51;Lombardi, 791 
2012 #52;Cooper, 2013 #25}.   792 
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Figure 1: Flow-chart on the management of patients with adrenal 793 
incidentalomas (overview) 794 
 795 
1 For patients with history of extra-adrenal malignancy, see special section 5.6.4 796 
2 only in patients with concomitant hypertension and /or hypokalemia 797 
3 only in patients with clinical or imaging features suggestive of adrenocortical carcinoma 798 
  799 
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5.2. Assessment of the risk of malignancy 800 
R.2.1 We recommend aiming to establish if an adrenal mass is benign or malignant at 801 
the time of initial detection.  802 
Reasoning 803 
It is critical to know if an adrenal mass is malignant or benign as clinical management is 804 
dependent on establishing this fact, regardless of whether the mass is functioning or not. 805 
Malignant lesions may need urgent surgical intervention and other therapies, and delay may 806 
cause harm. 807 
 808 
R.2.2 We recommend that all adrenal incidentalomas undergo an imaging procedure 809 
to determine if the mass is homogeneous and lipid-rich and therefore benign 810 
(XOOO). For this purpose, we primarily recommend the use of non-contrast CT 811 
(XOOO)  812 
 813 
R.2.3 We suggest that if the non-contrast CT is consistent with a benign adrenal 814 
mass (Hounsfield units ≤ 10) that is homogeneous and smaller than 4 cm no 815 
further imaging is required (XOOO).  816 
 817 
Reasoning 818 
In patients with no known extra-adrenal malignancy adrenal incidentalomas are likely to be 819 
benign. The non-contrast CT value is reflective of tissue density. Benign lesions including 820 
lipid rich adenoma, myelolipoma, fluid-filled homogenous cysts, and other soft tissue tumors 821 
(ganglioneuromas, some schwanomas) have low CT density ≤ 10 HU. Based on the 822 
systematic review and meta-analysis {Dinnes, 2016 #246}, in patients presenting without 823 
known malignancy a non-contrast CT with HU of ≤10 was only found in those with benign 824 
disease, whereas in patients with extra-adrenal malignancy 7% of cases with non-contrast 825 
HU ≤10 turned out to be malignant. 826 
Similar to CT, the results of MRI with chemical shift imaging are based on the lipid content of 827 
masses {Rodacki, 2014 #268;Seo, 2014 #269}. Unlike CT (or FDG-PET) MRI has the 828 
advantage of avoiding ionizing radiation and its attendant risks to the patient. However, the 829 
quantitative assessment of loss in signal intensity is not well standardized between the 830 
different studies and, therefore, evidence base for performance of MRI in the diagnosis of 831 
malignancy is insufficient to make strong recommendations. Moreover, the interpretation of 832 
the images might be more dependent on the experience of the radiologist than for CT 833 
assessment. In addition, the meta-analysis was not able to determine the diagnostic value of 834 
MRI due to the low number and quality of eligible studies. 835 
 836 
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In conclusion, the panel felt - despite the limited evidence - confident about the negative 837 
predictive value of non-contrast CT to recommend that additional imaging was not necessary 838 
when benign characteristics were found in an adrenal mass < 4 cm, especially as additional 839 
imaging may also risk false positive results and significant psychological and financial burden 840 
for patients and the health system, respectively. We acknowledge that the cutoff of 4 cm is 841 
not based on good evidence from clinical studies, but the panel felt it is necessary to provide 842 
clear guidance based on clinical experience.  843 
MRI with chemical shift has an even poorer evidence base with regard to its diagnostic value 844 
in excluding malignancy and therefore should be first choice only where a CT is less 845 
desirable (e.g. pregnancy, children). However, if an MRI with chemical shift is already 846 
performed and the results are unambiguous, a multidisciplinary expert team might judge this 847 
as sufficient for an individual patient.  848 
 849 
 850 
R.2.4 If the adrenal mass is indeterminate on non-contrast CT and the results of the 851 
hormonal work-up do not indicate significant hormone excess, there are three 852 
options that should be considered by a multidisciplinary team acknowledging 853 
the patient’s clinical context: immediate additional imaging with another 854 
modality, interval imaging in 6 to 12 months (non-contrast CT or MRI), or 855 
surgery without further delay. 856 
 857 
Reasoning 858 
Evidence of targeted evaluation for “second or third-line” imaging in patients with 859 
indeterminate adrenal mass is very poor (see section 4.1 and {Dinnes, 2016 #246} for 860 
details). However, the panel considered it important to provide some guidance for daily 861 
clinical practice (Table 4), although consensus was not reached other than agreeing that 862 
such discussions needed to be individualized and should take place within a multidisciplinary 863 
team meeting.  864 
The advantages and limitations of MRI with chemical shift are already discussed at R 2.3.  865 
Contrast washout CT has very limited and low quality evidence from studies {Dinnes, 2016 866 
#246}. CT washout is widely available but there is huge variability in the protocols applied 867 
and therefore poor comparability between studies and centers; in addition, the meta-analysis 868 
could only identify a single eligible study reporting CT washout study results, carried out in 869 
patients without a history of extra-adrenal malignancy.  870 
FDG-PET/CT has the advantage that the risk of false negative results (namely missing a 871 
malignant adrenal tumor) is quite low, and this refers mainly to a few subtypes of extra-872 
adrenal malignancies with low uptake {Karam, 2006 #207;Tsukamoto, 2007 873 
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#206;Zukotynski, 2012 #272;Ansquer, 2010 #273}. This procedure is, however, more 874 
expensive, not always easily available, and has the disadvantage that several benign adrenal 875 
tumors (e.g. functional adenomas or benign pheochromocytoma) may be FDG-positive 876 
{Timmers, 2009 #209;Alencar, 2011 #212}.  877 
 878 
 879 
Table 4: Imaging criteria suggesting a benign adrenal mass1  880 
Non-contrast CT 
 
≤ 10 HU 
 
MRI - chemical shift2 Loss of signal intensity on out-phase 
imaging consistent with lipid-rich 
adenoma 
CT with delayed contrast media 
washout2, 3 
Absolute washout > 60% 
Relative washout > 40% 
18F-FDG-PET2 Absence of FDG uptake or uptake less 
than the liver4 
 881 
1 these criteria apply only for masses with homogenous appearance, or masses that have other clear 882 
characteristics consistent with benign disease, e.g. myelolipoma. A homogeneous mass is defined as a lesion 883 
with uniform density or signal intensity throughout. The measurements/region of interest (ROI) should include at 884 
least 75% of a lesion without contamination by tissues outside the adrenal lesion. Inhomogeneous lesions 885 
should not be subjected to MRI or washout CT for further characterization.  886 
2 Evidence is weak for MRI, CT with contrast washout, and FDG-PET and no comparative studies on "second line 887 
imaging" are available. Thus, in this guideline we clearly recommend non-contrast CT as imaging procedure of 888 
choice.  889 
3 There is no clear evidence about the best time interval. We recommend 10 or 15 min.  890 
4 Certain metastasis (e.g. from kidney cancer or low grade lymphoma) may be FDG negative  891 
 892 
Whilst the panel was in favor of attempts to fully characterize the adrenal mass on imaging, 893 
due to the limitations summarized above, it considered that in patients with indeterminate 894 
results on non-contrast CT further imaging by one of the modalities detailed above should be 895 
arranged. Due to the lack of evidence and studies reporting direct comparison the panel was 896 
not able to clearly judge one method over another. Alternatively, in patients without a strong 897 
suspicion of malignancy and older patients, follow-up imaging 6-12 months after the initial 898 
scan could be undertaken. The rationale for a follow-up scan at 6-12 months is based on the 899 
principle that either primary adrenal malignancies or adrenal metastases are likely to 900 
increase in size over this time period; lack of growth may be taken as an indicator of benign 901 
disease in radiologically indeterminate lesions. The exact timing of this imaging should be 902 
individualized. However, especially in cases with a low likelihood of a malignant tumor the 903 
panel favors a time interval of 12 months. There are no published size or volume cut-offs 904 
commonly agreed or with evidence base to support that they indicate growth suggestive of 905 
malignancy; the expert panel agreed that an increase in > 20% of the largest tumor diameter 906 
together with an at least 5 mm increase in this diameter should be considered as suspicious. 907 
 908 
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 909 
R.2.5 We recommend against the use of an adrenal biopsy in the diagnostic work-up 910 
of patients with adrenal masses unless there is a history of extra-adrenal 911 
malignancy (see R6.3.5).  912 
 913 
Reasoning 914 
Adrenal biopsy has a limited role in evaluation of adrenal masses – mainly in diagnosis of 915 
extra/adrenal malignancy, lymphoma, infiltrative or infectious process. Even in such 916 
situations, adrenal biopsy should only be performed by an experienced radiologist and when 917 
it is required to guide further care. We particularly recommend against an adrenal biopsy if 918 
an adrenal mass is likely to be an adrenocortical carcinoma, because a biopsy of such a 919 
tumor runs the risk of tumor dissemination precluding an R0 resection (although this risk 920 
seems to be low {Williams, 2014 #152}). The only exception might be if a formal confirmation 921 
of the diagnosis is needed in an inoperable tumor to inform oncological management or as 922 
part of a clinical trial.   923 
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5.3. Assessment for hormone excess  924 
 925 
R.3.1 We recommend that every patient with an adrenal incidentaloma should 926 
undergo careful assessment including clinical examination for symptoms and 927 
signs of adrenal hormone excess.  928 
 929 
Reasoning 930 
All patients should undergo a careful evaluation with detailed history and physical 931 
examination since a second round evaluation may detect clues of overt hormone excess that 932 
were overlooked initially. For the clinical assessment and subsequent diagnostic procedures 933 
for Cushing’s syndrome, primary aldosteronism, and pheochromocytoma, we refer to 934 
guidelines of other societies {Nieman, 2008 #47;Lenders, 2014 #48;Funder, 2008 #276}.  935 
Rapidly developing hirsutism or virilization is a clinical indicator for an androgen-producing 936 
tumor, and should be addressed by measuring testosterone and androgen precursors, 937 
whereas recent onset of gynecomastia should trigger measurement of estradiol {Fassnacht, 938 
2009 #149;Fassnacht, 2004 #148;Libe, 2007 #157;Else, 2014 #153} (see also R.3.10).  939 
 940 
 941 
 942 
R.3.2 We recommend that all patients with adrenal incidentalomas undergo a 1-mg 943 
overnight dexamethasone suppression test to exclude cortisol excess (XXOO). 944 
R.3.3 We suggest interpretation of the results of the 1-mg overnight dexamethasone 945 
test as a continuous rather than categorical (yes/no) variable (XOOO). However, 946 
we recommend using serum cortisol levels post dexamethasone ≤ 50 nmol/l (≤ 947 
1.8 µg/dl) as a diagnostic criterion for the exclusion of autonomous cortisol 948 
secretion (XXOO).  949 
R.3.4 We suggest that post dexamethasone serum cortisol levels between 51 and 140 950 
nmol/l (1.9 - 5.0 µg/dl) should be considered as evidence of ‘possible 951 
autonomous cortisol secretion’ and cortisol levels post dexamethasone > 140 952 
nmol/l (> 5.0 µg/dl) should be taken as evidence of ‘autonomous cortisol 953 
secretion’. Additional biochemical tests to confirm cortisol secretory autonomy 954 
and assess the degree of cortisol secretion might be required (Figure 2). 955 
However, for the clinical management the presence of potentially cortisol-956 
related comorbidities (Table 2) and age of the patient are of major importance 957 
(Figure 2).  958 
 959 
 960 
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Reasoning 961 
A variety of diagnostic algorithms have been used to exclude cortisol excess or to define so-962 
called ‘subclinical hypercortisolism’, but in the literature there are no head to head 963 
comparisons between tests to assess their diagnostic performance (see section 4.2.1). 964 
However, the panel recommends the use of the 1-mg overnight dexamethasone test based 965 
on pathophysiological reasoning, simplicity, and the fact that the test was incorporated in the 966 
diagnostic algorithms of most studies. It is important to consider drugs or conditions that 967 
interfere with this test (see Appendix Table A3). In published guidelines and reviews variable 968 
thresholds have been recommended {Grumbach, 2003 #39;Young, 2007 #43;Terzolo, 2011 969 
#33;Tabarin, 2008 #59}. Several studies have used post dexamethasone serum cortisol 970 
values between 50 and 140 nmol/l (1.8 - 5.0 µg/dl) and/or required further tests to secure the 971 
diagnosis of ‘autonomous cortisol secretion’. However, in none of these additional tests was 972 
the performance convincing enough to ultimately establish diagnostic criteria.  973 
The panel appreciated that this ongoing debate reflects a biological continuum with no clear 974 
separation between non-functioning adenomas and functioning adenomas associated with 975 
some degree of cortisol excess. However, a value of ≤ 50 nmol/l (≤ 1.8 μg/dl) may be 976 
regarded as normal, excluding cortisol excess. This cut-off is supported by studies 977 
demonstrating that patients with post dexamethasone cortisol values > 50 nmol/l (> 1.8 μg/dl) 978 
have an increased morbidity or mortality {Debono, 2014 #19;Di Dalmazi, 2014 #20}. Since 979 
the probability of clinically relevant cortisol excess increases the higher the post-980 
dexamethasone serum cortisol value and that the principle of dexamethasone testing is 981 
based on pharmacological suppression of ACTH secretion, we propose the following 982 
terminology be used on biochemical grounds. For patients without overt Cushing's syndrome 983 
and a serum cortisol post dexamethasone between 51 and 140 nmol/l we propose the term 984 
‘possible autonomous cortisol secretion’ and for higher values the term "autonomous cortisol 985 
secretion". However, for the clinical management, the presence of potentially related 986 
comorbidities (Table 2) and age of the patient are of major relevance (Figure 2).  987 
The majority of panel members (but not all) preferred additional biochemical tests to confirm 988 
cortisol secretory autonomy and assess the degree of cortisol secretion. However, we 989 
acknowledge that use of several tests may be associated with an increased likelihood of at 990 
least one being a false positive result Nevertheless, we suggest measurement of basal 991 
morning plasma ACTH and to repeat the dexamethasone test after 3-12 months in all 992 
patients with ‘possible autonomous cortisol secretion’ and comorbidities. In patients with 993 
‘autonomous cortisol secretion’ we suggest the additional measurement of 24-h urinary free 994 
cortisol and/or late-night salivary cortisol (although few studies suggest a poor performance 995 
of this parameter in patients with incidentaloma). Following the concept that cortisol secretion 996 
in patients with 'autonomous cortisol secretion' is independent of ACTH, a higher dose of 997 
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dexamethasone (e.g. 3mg, 2x2mg, or 8mg) might also be reasonable as additional test. 998 
However, the published literature is too limited and controversial to make a clear statement 999 
on these tests.  1000 
 1001 
Figure 2: Assessment and management of ‘autonomous cortisol secretion’ in patients 1002 
with adrenal incidentalomas 1003 
1004 
  1005 
1 The majority of but not all panel members preferred additional biochemical tests to better judge the degree of 1006 
cortisol secretion. In patients with comorbidities, we suggest to measure plasma ACTH and to repeat the 1007 
dexamethasone test in 3-12 months. 1008 
2 We suggest additional biochemical tests to better judge the degree of cortisol secretion: plasma ACTH, 24-h 1009 
urinary free cortisol, (and/or late-night salivary cortisol), and repetition of the dexamethasone test in 3-12 1010 
months.  1011 
3 See Table 2 for potentially cortisol-related comorbidities. 1012 
4 Choice for surgery should always be individualized. 1013 
5 Need of follow-up by an endocrinologist 1014 
 1015 
 1016 
R.3.5 We recommend against considering ‘autonomous cortisol secretion’ as a 1017 
condition with a high risk for the development of overt Cushing’s syndrome 1018 
(XXOO). 1019 
 1020 
Reasoning 1021 
Studies reporting on follow-up of patients with adrenal incidentalomas have uniformly found a 1022 
very low percentage (< 1%) of patients with ‘autonomous cortisol secretion’ progressing to 1023 
overt Cushing’s syndrome {Cawood, 2009 #35;Barzon, 1999 #112;Barzon, 2003 #38;Bernini, 1024 
2005 #137;Fagour, 2009 #136;Libe, 2002 #123;Terzolo, 2005 #135;Terzolo, 1998 1025 
#134;Nieman, 2015 #142}. 1026 
 1027 
 1028 
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R.3.6 We recommend screening patients with ‘possible autonomous cortisol 1029 
secretion’ or ‘autonomous cortisol secretion’ for hypertension and type 2 1030 
diabetes mellitus (XOOO) and suggest offering appropriate treatment of these 1031 
conditions. 1032 
 1033 
Reasoning 1034 
Studies from different research groups have consistently demonstrated an association 1035 
between cortisol excess and hypertension and hyperglycemia {Terzolo, 2005 #146;Terzolo, 1036 
2005 #135;Tauchmanova, 2002 #143;Emral, 2003 #144;Reincke, 1996 #166;Bernini, 2003 1037 
#164;Di Dalmazi, 2012 #12;Fernandez-Real, 1998 #165;Morelli, 2010 #163;Rossi, 2000 1038 
#162}. The association with dyslipidemia is less proven, although biologically plausible. 1039 
There is also evidence that patients with cortisol excess are at increased risk of 1040 
cardiovascular events and excess mortality {Debono, 2014 #19;Di Dalmazi, 2014 #20}. 1041 
Therefore, the panel recommended screening for these conditions, which are well known 1042 
independent cardiovascular risk factors and which may be driven by cortisol excess, and to 1043 
treat them according to current guidelines. 1044 
 1045 
 1046 
R.3.7 We suggest screening patients with ‘autonomous cortisol secretion’ for 1047 
asymptomatic vertebral fractures (XOOO) and to consider appropriate 1048 
treatment of these conditions (XOOO).  1049 
 1050 
Reasoning  1051 
Several studies, although mainly from a single research group, have demonstrated an 1052 
association between autonomous cortisol secretion and an increased risk of vertebral 1053 
fractures {Hadjidakis, 2003 #145;Chiodini, 2004 #18;Chiodini, 2009 #53;Chiodini, 2010 1054 
#11;Eller-Vainicher, 2012 #13;Morelli, 2011 #14}. Although most of the fractures are 1055 
asymptomatic, the panel suggests screening patients with ‘autonomous cortisol secretion’ for 1056 
vertebral fractures at least once at the time of diagnosis. This may be done by re-evaluating 1057 
the available images (if a CT was performed) or by plain X-ray. The panel did not reach 1058 
consensus on recommending assessment of bone mineral density by dual-energy x-ray 1059 
absorptiometry (DXA). If osteoporosis is present, active treatment should be considered. If 1060 
there is no other likely explanation for the osteoporosis, removal of the adrenal adenoma 1061 
might be considered (see R3.8).  1062 
 1063 
 1064 
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R.3.8 We suggest an individualized approach in patients with ‘autonomous cortisol 1065 
secretion’ due to a benign adrenal adenoma and comorbidities potentially 1066 
related to cortisol excess for adrenal surgery (XOOO). Age, degree of cortisol 1067 
excess, general health, comorbidities and patient’s preference should be taken 1068 
into account. In all patients considered for surgery, ACTH-independency of 1069 
cortisol excess should be confirmed.  1070 
 1071 
Reasoning 1072 
Due to the limitations of current literature, especially the lack of high-quality randomized 1073 
trials, the panel could not reach consensus on the exact indication for surgery for 1074 
‘autonomous cortisol secretion’. The panel appreciated that there is some evidence of 1075 
improvement of hypertension, hyperglycemia and dyslipidemia with surgery but this is based 1076 
on low quality data. However, no data are available on clinically relevant endpoints (e.g. 1077 
mortality or major cardiovascular events). Thus, the decision to undertake surgery should be 1078 
individualized taking into account factors that are linked to surgical outcome, such as 1079 
patient’s age, duration and evolution of comorbidities and their degree of control, and 1080 
presence and extent of end organ damage. Because it is not possible to be sure that surgical 1081 
intervention will normalize or improve the clinical phenotype of an individual patient, there 1082 
was no complete agreement within the panel with regard to the optimal management of 1083 
these patients. Approaches varied between two ends of the spectrum. Overall, the group 1084 
agreed that there is an indication of surgery in a patient with post dexamethasone cortisol > 1085 
140 nmol/l (> 5 µg/dl) and the presence of at least two comorbidities potentially related to 1086 
cortisol excess (e.g. type 2 diabetes, hypertension, obesity, osteoporosis), of which at least 1087 
one is poorly controlled by medical measures. Conversely, there is no reason for surgery, 1088 
when serum cortisol post dexamethasone is < 140 nmol/l (< 5 µg/dl) and no comorbidities 1089 
are present. However, some panel members favor a more proactive approach, for example 1090 
considering surgical intervention, especially in younger patients with ‘possible autonomous 1091 
cortisol’ secretion and less comorbidities potentially related to cortisol excess, even if 1092 
controlled by medical therapy. 1093 
However, there was consensus that when surgery is considered due to ‘autonomous cortisol 1094 
secretion’, ACTH-independency has to be proven by a suppressed or low basal morning 1095 
plasma ACTH. If not, other reasons of cortisol excess have to be considered.  1096 
 1097 
 1098 
R.3.9 We recommend excluding pheochromocytoma by measurement of plasma free 1099 
metanephrines or urinary fractionated metanephrines. 1100 
 1101 
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Reasoning:  1102 
For details we refer to the most recent guidelines of other societies (e.g. {Lenders, 2014 1103 
#48}). Of note, there are clinically silent pheochromocytomas {Haissaguerre, 2013 1104 
#150;Erickson, 2001 #241;Kopetschke, 2009 #242} that might lead to hemodynamic 1105 
instability during surgical excision {Lafont, 2015 #151}. Thus, metanephrines should be 1106 
measured in normotensive patients and the diagnosis of pheochromocytoma should be 1107 
considered in patients with borderline values of metanephrines and indeterminate imaging 1108 
features on CT.  1109 
In adrenal lesions with imaging criteria of an adenoma the likelihood of a pheochromocytoma 1110 
is extremely low {Sane, 2012 #210;Schalin-Jantti, 2015 #217}. Thus, it seems to be 1111 
reasonable to avoid measuring metanephrines in patients with clear evidence of an adrenal 1112 
adenoma, but definitive data in this area are lacking. 1113 
 1114 
 1115 
R.3.10 In patients with concomitant hypertension or unexplained hypokalemia, we 1116 
recommend the use of the aldosterone / renin ratio to exclude primary 1117 
aldosteronism. 1118 
 1119 
Reasoning:  1120 
For details we refer to the most recent guidelines of other societies (e.g. {Funder, 2008 1121 
#276}). 1122 
 1123 
 1124 
R.3.11 We suggest measurement of sex hormones and steroid precursors in patients 1125 
with imaging or clinical features suggestive of adrenocortical carcinoma.  1126 
 1127 
Reasoning:  1128 
Adrenocortical carcinoma is associated in more than half of cases with elevated sex 1129 
hormones and steroid precursors {Berruti, 2012 #156;Fassnacht, 2013 #54;Libe, 2007 1130 
#157;Else, 2014 #153}. The panel does not recommend measurement of these hormones in 1131 
patients with adrenal incidentalomas on a routine basis, but in cases with indeterminate 1132 
adrenal mass by imaging or clinical signs for androgen excess, significantly increased sex 1133 
hormones or precursors might clearly point towards adrenocortical carcinoma. Thus, 1134 
measurement of serum DHEA-S, androstenedione, 17-hydroxyprogesterone as well as 1135 
testosterone in women and estradiol in men and postmenopausal women can prove the 1136 
adrenocortical nature of the adrenal mass. However, the panel acknowledges that the 1137 
published evidence for this suggestion is very low {Arlt, 2011 #34;Fassnacht, 2013 #54}. A 1138 
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very promising new tool to discriminate benign from malignant adrenocortical tumors appears 1139 
the analysis of a comprehensive urinary steroid profile measured by GC-MS or LC-MS {Arlt, 1140 
2011 #34;Kerkhofs, 2015 #216}.   1141 
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5.4. Surgical treatment  1142 
 1143 
R.4.1 We recommend adrenalectomy as the standard of care for unilateral adrenal 1144 
tumors with clinically significant hormone excess.  1145 
 1146 
Reasoning:  1147 
As covered by several other guidelines, there is consensus that adrenal tumors leading to 1148 
clinically significant hormone excess (e.g. primary aldosteronism, Cushing syndrome or 1149 
pheochromocytoma) should be surgically removed {Lenders, 2014 #48;Funder, 2008 1150 
#276;Nieman, 2015 #138}. The guideline group is convinced that for these tumors the same 1151 
rules regarding the surgical approach should apply as for endocrine inactive tumors (see 1152 
below). There are no substantiated reasons why the surgical approach for hormone-1153 
producing tumors should differ from that in endocrine inactive tumors (R4.3-5). 1154 
 1155 
 1156 
R.4.2 We recommend against performing surgery in patients with an asymptomatic, 1157 
non-functioning unilateral adrenal mass and obvious benign features on 1158 
imaging studies (XOOO). 1159 
 1160 
Reasoning: 1161 
Most adrenal incidentalomas are non-functioning benign lesions (e.g. adenomas, 1162 
myelolipomas) that do not cause harm. Therefore, there is broad consensus that the majority 1163 
of these adrenal masses do not require surgery. The guideline group defined two criteria that 1164 
need to be fulfilled to allow characterization of a unilateral adrenal lesion as not harmful: (i) 1165 
imaging criteria indicating a benign lesion (see section 5.2, Table 4) (ii) no relevant endocrine 1166 
activity (see section 5.3).  1167 
There was considerable discussion by the group if a certain cutoff of size should be a factor 1168 
to consider surgery. There was consensus that a tumor with a diameter of ≤ 4 cm with benign 1169 
imaging features does not require surgery, accepting that this size cutoff is arbitrary. 1170 
However, due to the paucity of follow-up data on the natural history of large apparently 1171 
benign adrenal incidentalomas the panel was divided on the approach to the management of 1172 
patients with larger lesions. One approach is to rely on imaging criteria only to determine if a 1173 
lesion is benign irrespective of size. Alternatively, because of clinician or patient uncertainty 1174 
about the increasing incidence of malignancy the larger is size, surgery may be considered in 1175 
larger lesions (e.g. > 4 cm) even if imaging characteristics suggest a benign nature of the 1176 
mass, allowing for an individualized approach. We voted against a certain cutoff which 1177 
indicates that surgery has to be performed. However, we acknowledge that with a larger 1178 
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tumor size patients and clinicians might feel increasingly uncomfortable, but again an 1179 
individualized approach was deemed most appropriate. 1180 
 1181 
 1182 
R.4.3 We suggest performing laparoscopic adrenalectomy in patients with unilateral 1183 
adrenal masses with radiological findings suspicious of malignancy and a 1184 
diameter ≤ 6 cm, but without evidence of local invasion (XOOO). 1185 
R.4.4 We recommend performing open adrenalectomy for unilateral adrenal masses 1186 
with radiological findings suspicious of malignancy and signs of local invasion 1187 
(XOOO). 1188 
R.4.5 We suggest an individualized approach in patients that do not fall in one of the 1189 
above mentioned categories (XOOO).  1190 
 1191 
Reasoning: 1192 
The main threat of a unilateral adrenal mass, which is suspected to be malignant, is 1193 
adrenocortical carcinoma. For adrenocortical carcinoma without metastases, surgery is the 1194 
most important single therapeutic measure. Thus, the high expertise of the surgeon is of 1195 
major importance. Although we cannot provide a specific number of required operations per 1196 
year, we have no doubts that surgical volume correlates with better outcome. As summarized 1197 
above (section 4.1.3) there are nine cohort studies on surgery for localized adrenocortical 1198 
carcinoma comparing laparoscopic versus open adrenalectomy, each with more than ten 1199 
patients per group {Brix, 2010 #24;Cooper, 2013 #25;Donatini, 2014 #26;Fossa, 2013 1200 
#27;Lombardi, 2012 #28;Miller, 2010 #29;Miller, 2012 #30;Mir, 2013 #31;Porpiglia, 2010 1201 
#32}, but these studies are, however, hampered by methodological flaws, and importantly 1202 
none was randomized. Nevertheless, based on these data and the clinical experience of the 1203 
guideline group members, it was judged that laparoscopic adrenalectomy may be justified for 1204 
tumors with radiological signs of malignancy but only where there was no evidence of local 1205 
invasion. For this approach the group arbitrarily chose a cut-off size for the adrenal tumor of 1206 
≤ 6 cm, because for this size it is believed that laparoscopic adrenalectomy is feasible 1207 
without rupture of tumor capsule (a major risk factor for recurrence), and is beneficial for the 1208 
patient (e.g. less pain, shorter hospital stay). However, with increasing tumor size risk of 1209 
tumor capsule rupture may increase. If during surgery there is a risk of tumor capsule 1210 
rupture, conversion to open procedure should be performed. We acknowledge that the cutoff 1211 
of 6 cm for laparoscopic vs. open adrenalectomy is not based on good evidence from clinical 1212 
studies, and we recognize that laparoscopic adrenalectomy for tumors < 6 cm is common 1213 
practice in most centers. However, this cutoff by no means indicates that every tumor smaller 1214 
than 6 cm has to undergo laparoscopic adrenalectomy and every tumor larger than 6 cm 1215 
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open adrenalectomy. We are convinced that in many cases an individualized decision 1216 
process is required to find the best surgical approach for a given patient. This is also true for 1217 
all patients that do not fall in one of the categories described in R.4.2 - 4.4.  1218 
 1219 
There are no sufficiently powered studies published on the approach to patients with stage III 1220 
adrenocortical carcinoma (local invasion, lymph nodes metastases, or tumor thrombus in the 1221 
renal vein or vena cava). However, the guideline group unanimously voted for open 1222 
adrenalectomy as standard procedure for this stage of disease.  1223 
 1224 
 1225 
R.4.6 We recommend perioperative glucocorticoid treatment at major surgical stress 1226 
doses, as recommended by guidelines, in all patients undergoing surgery for 1227 
an adrenal tumor where there is evidence of ‘possible autonomous cortisol 1228 
secretion’ or ‘autonomous cortisol secretion’.  1229 
 1230 
Reasoning: 1231 
Autonomous cortisol secretion may lead to adrenal insufficiency after removal of the adrenal 1232 
source of cortisol (even in patients with incompletely suppressed ACTH {Eller-Vainicher, 1233 
2010 #214}). Therefore, the group unanimously recommends intra- and post-operative 1234 
glucocorticoid replacement, preferably by hydrocortisone in patients with an adrenal tumor 1235 
and evidence for ‘(possible) autonomous cortisol secretion’ (post dexamethasone cortisol > 1236 
50 nmol/l (> 1.8 µg/dl)) even if there are no clinical sign of cortisol excess. This should follow 1237 
the suggestions for major stress dose replacement as per a recent international guideline 1238 
{Bornstein, 2016 #211}. Postoperatively, the glucocorticoid dose should be tapered 1239 
individually by a physician experienced in this clinical scenario.   1240 
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Figure 3: Flow-chart on the management of adrenal masses considered for 1241 
surgery 1242 
         1243 
 1244 
1 ‘autonomous cortisol secretion’ is not automatically judged as clinically relevant (see section 5.3 for details). 1245 
2 in tumors with benign radiological features and a tumor size > 4 cm, surgery might also be individually 1246 
considered (see text)  1247 
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5.5 Follow-up of patients not undergoing adrenal surgery after initial 1248 
assessment 1249 
 1250 
R.5.1 We suggest against further imaging during follow-up in patients with an adrenal 1251 
mass < 4cm with clear benign features on imaging studies (XOOO).  1252 
 1253 
Reasoning 1254 
Amongst more than 2300 patients included in published follow-up studies {Cawood, 2009 1255 
#35;Terzolo, 2011 #33} there is no report of occurrence of adrenal malignancy in adrenal 1256 
incidentalomas displaying typical features of adrenocortical adenomas at initial imaging 1257 
studies. Therefore, the panel does not support repeating imaging investigations if the initial 1258 
work-up is unequivocally consistent with a benign lesion. However, many patients with 1259 
adrenal incidentalomas > 4 cm in diameter have undergone adrenalectomy in the past and 1260 
the literature on follow-up of non-operated large adrenal incidentalomas is scarce. Thus, and 1261 
similar to the discussion on the surgical treatment (R.4.2), some panel members argued that 1262 
one follow-up imaging (non-contrast CT or MRI) after 6-12 months might be considered in 1263 
lesions > 4 cm.  1264 
 1265 
 1266 
R.5.2 In patients with an indeterminate adrenal mass (by imaging), opting not to 1267 
undergo adrenalectomy following initial assessment, we suggest a repeat non-1268 
contrast CT or MRI after 6-12 months to exclude significant growth (XOOO). We 1269 
suggest surgical resection if the lesion enlarges by more than 20% (in addition 1270 
to at least a 5 mm increase in maximum diameter) during this period. If there is 1271 
growth of the lesion below this threshold, additional imaging again after 6-12 1272 
months might be performed.  1273 
 1274 
Reasoning 1275 
Contrary to benign adrenal tumors that may exhibit a slow growth tendency with time, 1276 
malignant adrenal lesions (mostly adrenocortical carcinoma and metastases) are almost 1277 
invariably characterized by a rapid growth within months {Else, 2014 #153;Fassnacht, 2013 1278 
#54;Berruti, 2012 #156}. Consequently, the panel recommends performing follow-up imaging 1279 
studies in adrenal incidentaloma, in which the benign nature cannot be established with 1280 
certainty at initial evaluation, in order to recognize early a rapidly growing mass. Many 1281 
clinicians would opt for surgical removal if the mass is of larger size and cannot be 1282 
determined as benign with certainty.  1283 
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Lack of growth of an adrenal mass over a period of 6-12 months makes a malignant mass 1284 
highly unlikely while surgery is recommended if significant rapid growth is observed. There is 1285 
no generally accepted definition of significant growth of an adrenal tumor. However, the 1286 
panel proposes an adaptation of the RECIST 1.1 criteria {Eisenhauer, 2009 #56}. These 1287 
criteria, which are used in most oncological trials, define progress by an increase of 20% of 1288 
the largest diameter. Although RECIST 1.1 criteria are not validated for the differentiation 1289 
between benign and malignant adrenal tumors, the 20% cut-off together with an absolute 1290 
increase of at least 5 mm in diameter may serve as warning for significant growth and 1291 
reconsideration then given for surgical excision.  1292 
The panel is aware that there are exceptional cases of malignant adrenal tumor without 1293 
significant growth for several years {Nogueira, 2015 #55;Ozsari, 2015 #158}. However, this 1294 
can be considered a very rare exception and does not justify following all patients with an 1295 
adrenal mass with repeated imaging over years. However, in case there is some measurable 1296 
growth (10-20%) that does not qualify for the above-mentioned criteria, additional follow-up 1297 
imaging should be considered.  1298 
 1299 
 1300 
R.5.3 We suggest against repeated hormonal work-up in patients with a normal 1301 
hormonal work-up at initial evaluation unless new clinical signs of endocrine 1302 
activity appear or there is worsening of comorbidities (e.g. hypertension and 1303 
type 2 diabetes) (XOOO). 1304 
 1305 
Reasoning 1306 
The pooled risk of developing clinically relevant hormonal excess (e.g. primary 1307 
aldosteronism, Cushing’s syndrome and pheochromocytoma) is below 0.3% in patients with 1308 
initial hormonal work-up consistent with a non-functioning lesion {Cawood, 2009 #35;Terzolo, 1309 
2011 #33}. 1310 
Development of ‘autonomous cortisol secretion’ without signs of overt Cushing’s syndrome is 1311 
the most frequently reported event during the follow-up and may occur in 8 to 14% of 1312 
patients with non-functioning adrenal incidentalomas. Owing to the risk of false positive 1313 
results {Elamin, 2008 #159} the panel does not recommend systematic follow-up hormonal 1314 
investigations in patients with non-functioning adrenal incidentalomas at initial evaluation (ie 1315 
cortisol ≤ 50 nmol/l (≤ 1.8 µg/dl) post 1-mg overnight dexamethasone test).  1316 
 1317 
 1318 
R.5.4 In patients with ‘autonomous cortisol secretion’ without signs of overt 1319 
Cushing’s syndrome (see Figure 2), we suggest annual follow-up with re-1320 
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assessment for cortisol excess and careful assessment of comorbidities 1321 
potentially related to cortisol excess (XOOO). Based on the outcome of this 1322 
evaluation the potential benefit of surgery should be considered.  1323 
 1324 
Reasoning 1325 
As discussed above, it is extremely rare that patients will develop overt Cushing’s syndrome 1326 
during follow-up. However, as elaborated in section 5.3, the panel considers ‘autonomous 1327 
cortisol secretion’ as a condition associated with several comorbidities (Table 2). Therefore, 1328 
the panel recommends annual clinical follow-up in patients with ‘autonomous cortisol 1329 
secretion’ and in patients with both ‘possible autonomous cortisol secretion’ and potentially 1330 
associated comorbidities, in whom an initial decision against surgery was made (Figure 2). 1331 
Clinical follow-up should include evaluation of potentially cortisol excess-related 1332 
comorbidities. The presence or worsening of these conditions should prompt hormonal re-1333 
evaluation at any time during follow-up. Appropriate symptomatic treatment and 1334 
reconsideration of surgical removal of the adrenal mass is recommended, in line with the 1335 
observed changes in the clinical and hormonal status of the patient.  1336 
In the absence of evidence, we suggest that follow-up by an endocrinologist beyond 2-4 1337 
years is not needed in patients with no relevant change during this time.   1338 
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5.6. Special circumstances 1339 
 1340 
5.6.1 Patients with bilateral adrenal incidentalomas 1341 
R.6.1.1 We recommend that for patients with bilateral adrenal masses each adrenal 1342 
lesion is assessed at the time of initial detection according to the same 1343 
imaging protocol as for unilateral adrenal masses to establish if either or both 1344 
lesions are benign or malignant. 1345 
 1346 
Reasoning: 1347 
In most cases bilateral adrenal masses represent benign bilateral adrenocortical disease: 1348 
either bilateral adenomas, macronodular hyperplasia, or distinct bilateral nodules with normal 1349 
or atrophic cortex intervening. The possibility of metastases (especially in patients with 1350 
known malignancy), adrenal lymphoma or bilateral pheochromocytomas should also be 1351 
considered. Moreover, bilateral adrenal masses may represent co-occurrence of different 1352 
entities, such as adenoma, pheochromocytoma, cyst, myelolipoma, adrenocortical 1353 
carcinoma, etc. Therefore the best approach is to separately characterize each lesion 1354 
following the recommendations in R.2.2 and R.2.3.  1355 
 1356 
 1357 
R.6.1.2 We recommend that all patients with bilateral adrenal incidentalomas should 1358 
undergo clinical and hormonal assessment identical to that in patients with 1359 
unilateral adrenal incidentaloma. The same applies for the assessment of 1360 
comorbidities that might be related to ‘autonomous cortisol secretion’ (Table 1361 
2). In addition, 17-hydroxyprogesterone should be measured to exclude 1362 
congenital adrenal hyperplasia, and testing for adrenal insufficiency should 1363 
be considered if suspected on clinical grounds or if imaging suggests 1364 
bilateral infiltrative disease or hemorrhages. 1365 
 1366 
Reasoning: 1367 
Hormonal excess in patients with bilateral adrenal masses may originate either from one of 1368 
the lesions or bilaterally. Cushing’s syndrome, primary aldosteronism, and 1369 
pheochromocytoma(s) may all be encountered. For the clinical assessment of these entities 1370 
we refer to guidelines of other societies {Nieman, 2008 #47;Lenders, 2014 #48;Funder, 2008 1371 
#276}. As for unilateral lesions, subtle autonomous cortisol secretion is the most common 1372 
secretory abnormality and, therefore, requires a full assessment of related comorbidities. 1373 
Occasionally, bilateral adrenal enlargement is due to congenital adrenal hyperplasia and 1374 
49 
ESE and ENSAT guideline on adrenal incidentaloma v.21.3.2016 
therefore the additional measurement of 17-hydroxyprogesterone should be performed 1375 
{Jaresch, 1992 #190}. However, the measurement of 17-hydroxyprogesterone to identify the 1376 
most common cause of congenital adrenal hyperplasia, 21-hydroxylase deficiency, as the 1377 
cause of bilateral adrenal hyperplasia should be interpreted with caution. In some cases 1378 
increased levels of 17-hydroxyprogesterone may represent increased secretion of steroid 1379 
precursors from the lesion(s) {Del Monte, 1995 #191} especially in malignant tumors or in 1380 
bilateral macronodular adrenal hyperplasia. In these cases low/suppressed ACTH levels may 1381 
argue against congenital adrenal hyperplasia. Bilateral adrenal enlargement due to 1382 
metastatic disease rarely causes adrenal insufficiency (for details see R.6.3.6).  1383 
 1384 
 1385 
R.6.1.3 We suggest that for patients with bilateral incidentaloma the same 1386 
recommendations regarding the indication of surgery and follow-up are used 1387 
as for patients with unilateral adrenal incidentalomas. 1388 
 1389 
Reasoning: 1390 
‘Autonomous cortisol secretion’ is more frequently encountered in patients with bilateral 1391 
adrenal incidentalomas, compared to those with unilateral lesions, but there is no published 1392 
evidence that they should be managed differently. However, in the few cases, in whom 1393 
bilateral surgery is potentially indicated (e.g. bilateral pheochromocytomas), one can 1394 
consider adrenal-sparing surgery {Castinetti, 2015 #192}.  1395 
 1396 
 1397 
R.6.1.4 We suggest that in patients with bilateral adrenal masses bilateral 1398 
adrenalectomy is not performed for ‘autonomous cortisol secretion’ without 1399 
clinical signs of overt Cushing’s syndrome. In selected patients a unilateral 1400 
adrenalectomy of the dominant lesion might be considered using an 1401 
individualized approach considering age, degree of cortisol excess, general 1402 
condition, comorbidities and patient preference. 1403 
 1404 
Reasoning: 1405 
Surgery is a complex decision for patients with bilateral adrenal incidentalomas. This is 1406 
because, in the absence of clinical signs of overt Cushing’s syndrome, the clinical situation 1407 
may not be severe enough to prompt surgical management. Moreover, bilateral 1408 
adrenalectomy is associated with higher morbidity compared to unilateral surgery, the patient 1409 
is dependent lifelong on adrenal replacement therapy and at risk for life-threatening adrenal 1410 
crisis. In addition, glucocorticoid replacement is frequently sub-optimal and cannot mimic the 1411 
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diurnal profile of endogenous cortisol, and may result in persisting exposure to subtle cortisol 1412 
excess. In bilateral macronodular adrenal hyperplasia there is limited evidence of beneficial 1413 
effects of unilateral adrenalectomy {Debillon, 2015 #129;Perogamvros, 2015 #213}. In most 1414 
published studies excision of the largest lesion was performed, based on observations that 1415 
the size of the adrenal lesion correlates with the degree of cortisol excess {Debillon, 2015 1416 
#129}. Adrenal venous sampling may aid in the lateralization of cortisol excess but the data 1417 
are very weak {Young, 2008 #302}. Due to the limited available evidence, an individualized 1418 
approach, considering age, degree of cortisol excess, general condition, comorbidity status 1419 
and patient’s preference is suggested. However, when bilateral surgery is potentially 1420 
indicated, cortical sparing adrenalectomy might be considered {Vassiliadi, 2011 #195}. 1421 
In cases of bilateral macronodular hyperplasia, especially in younger patients or those with 1422 
relevant family history, family screening with 1 mg dexamethasone test can be considered.  1423 
A number of patients will have evidence of the presence of aberrant receptors, but routine 1424 
assessment by the complex testing {Vassiliadi, 2011 #197;Bourdeau, 2001 #201;Lacroix, 1425 
2009 #199;Lacroix, 2004 #200;Lacroix, 2010 #198;Lacroix, 2001 #202;Libe, 2010 1426 
#203;Lacroix, 2015 #140} that is needed to establish the presence of these receptors is hard 1427 
to justify based on the fact that in the majority of patients long-term management will not be 1428 
based on knowledge of receptor activity, and therefore we suggest that these tests should be 1429 
confined to clinical studies. 1430 
 1431 
 1432 
5.6.2 Adrenal incidentalomas in young or elderly patients 1433 
R.6.2.1 We recommend urgent assessment of an adrenal mass in children, 1434 
adolescents, pregnant women and adults < 40 years of age because of a 1435 
higher likelihood of malignancy.  1436 
R.6.2.2 We suggest the use of MRI rather than CT in children, adolescents, pregnant 1437 
women and adults < 40 years of age if dedicated adrenal imaging is required. 1438 
R.6.2.3 We recommend that the management of patients with poor general health and 1439 
a high degree of frailty be kept in proportion to potential clinical gain. 1440 
 1441 
Reasoning 1442 
The incidence of adrenal incidentaloma shows clear variation with age, with the majority of 1443 
patients presenting in the 5th to 7th decade of life. Overall incidence of adrenal incidentaloma 1444 
in a population undergoing routine imaging not related to suspected adrenal disease is 1445 
reported as 1-4 % {Ferreira, 2005 #128;Bovio, 2006 #45;Hammarstedt, 2010 1446 
#126;Davenport, 2011 #125}. While 10 % or more of individuals older than 70 years harbor 1447 
an adrenal mass detectable upon imaging or autopsy, adrenal nodules in individuals < 40 1448 
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years are much less prevalent and are a rarity in children and young adults. Consequently, 1449 
work-up in young patients including pregnant women has to be pursued with urgency as the 1450 
risk of malignancy in this cohort is much higher. Conversely, a smaller adrenal incidentaloma 1451 
in an elderly patient can be assumed to have a very low pre-test probability of malignancy. 1452 
Thus work-up in elderly patients only needs to be expedited if there are clear signs of 1453 
suspicion of malignancy and the extent of imaging work-up should be kept in proportion to 1454 
the clinical performance status of the individual and the expected clinical gain of further work-1455 
up in an affected patient. 1456 
As radiation safety is even more important in the young patient, we suggest MRI as the 1457 
preferred imaging technique. However, adapted low-dose unenhanced CT protocols can 1458 
limited radiation exposure and can be considered as an alternative (especially if the 1459 
availability of MRI is limited). 1460 
 1461 
 1462 
5.6.3  Patients with a newly diagnosed adrenal mass and a history of extra-1463 
adrenal malignancy (Figure 4) 1464 
 1465 
General remarks:  1466 
In principle, for adrenal masses in patients with known extra-adrenal malignancy the same 1467 
recommendations apply as described above. However, in this situation it is particularly 1468 
important to consider the different pre-test probabilities and the life expectancy of the patient. 1469 
In patients with underlying extra-adrenal malignancy and an indeterminate adrenal mass, 1470 
studies revealed a high rate of malignancy, up to 70%. Although age specific subgroup 1471 
analysis is not available, it can be assumed that older patients have a higher likelihood of co-1472 
existent benign adenomas. Conversely younger patients with an underlying malignancy are 1473 
more likely to have a metastasis. 1474 
 1475 
 1476 
R.6.3.1  We recommend measurement of plasma or urinary metanephrines to exclude 1477 
pheochromocytoma in patients with extra-adrenal malignancy with an 1478 
indeterminate mass, even if the adrenal mass is likely to be a metastasis. We 1479 
suggest additional hormonal work-up based on an individualized approach.  1480 
 1481 
Reasoning 1482 
Pheochromocytomas are almost impossible to distinguish from metastasis by conventional 1483 
imaging (including FDG-PET/CT). Furthermore, pheochromocytomas can lead to life-1484 
threatening complications, especially in the context of medical interventions (surgery, 1485 
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biopsies etc.) {Mannelli, 2012 #161;Stolk, 2013 #160;Lenders, 2014 #48}. Additional 1486 
hormonal work-up should depend on the stage of the extra-adrenal malignancy and life 1487 
expectancy. Evidence of adrenal hormone excess indicating that the mass is a primary 1488 
adrenal lesion can influence management of the extra-adrenal malignancy.  1489 
 1490 
R.6.3.2 We suggest that in patients with a history of extra-adrenal malignancy FDG-1491 
PET/CT, performed as part of investigations for the underlying malignancy, 1492 
can replace other adrenal imaging techniques.  1493 
 1494 
Reasoning: 1495 
18FDG-PETCT may add additional value in the assessment of an indeterminate adrenal 1496 
mass, however, the evidence base is insufficient to make strong recommendations {Dinnes, 1497 
2016 #246}. Both qualitative and quantitative interpretations of 18FDG-PETCT imaging have 1498 
been studied, but these vary considerably. An adrenal lesion / liver ratio of 1.53-1.8 were 1499 
investigated in patients with history of extra-adrenal malignancy (2 studies {Kunikowska, 1500 
2014 #121;Villar Del Moral, 2010 #104}, 117 lesions) and found to have sensitivity of 82% 1501 
(95%CI 41-97%) and specificity of 96% (95%CI 76-99%) to detect malignant disease.  1502 
 1503 
 1504 
R.6.3.3 We recommend that in patients with a history of extra-adrenal malignancy 1505 
adrenal lesions characterized as benign by non-contrast CT require no further 1506 
specific adrenal imaging follow-up. 1507 
 1508 
Reasoning 1509 
See details R2.2-4. However, we acknowledge that the currently available data suggest a 1510 
false negative rate of 7% in this population.  1511 
 1512 
 1513 
R.6.3.4 For indeterminate lesions in patients with a history of extra-adrenal 1514 
malignancy, we recommend imaging follow-up assessing the potential growth 1515 
of the lesion at the same interval as imaging for the primary malignancy. 1516 
Alternatively, FDG-PET/CT, surgical resection or a biopsy (see also R.6.3.5) 1517 
can be considered. 1518 
 1519 
Reasoning: 1520 
In many patients with advanced extra-adrenal malignancy (e.g. with multiple metastases) the 1521 
knowledge of the origin of the adrenal mass will not alter the clinical management of the 1522 
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patient. If, however, clinical management would be altered by the demonstration that the 1523 
adrenal lesion is a metastasis, then every effort should be made to allow this discrimination. 1524 
If the adrenal mass is potentially the only metastasis and if resection of this metastasis 1525 
seems to be reasonable from an oncological point of view, then surgery should be 1526 
considered. Regarding biopsy, we recommend applying the criteria provided in R.6.3.5.  1527 
 1528 
 1529 
R.6.3.5 We suggest performing a biopsy of an adrenal mass only if all of the following 1530 
criteria are fulfilled: (i) the lesion is hormonally inactive (in particular, a 1531 
pheochromocytoma has been excluded), (ii) the lesion has not been 1532 
conclusively characterized as benign by imaging, and (iii) management would 1533 
be altered by knowledge of the histology.  1534 
 1535 
Reasoning: 1536 
Adrenal biopsy may present with a significant non-diagnostic rate and a potential for 1537 
complications {Tamhane, 2016 #248}. Biopsy is only recommended for masses not 1538 
characterized as benign on cross-sectional imaging and where a biopsy result would affect 1539 
clinical treatment decisions. In patients with no other obvious metastatic lesions and when 1540 
surgical removal of the lesion is an option, FDG-PET/CT should be considered in order to 1541 
exclude metastases outside the adrenal that were not visualized by CT or MRI. Adrenal 1542 
biopsy presents with lower diagnostic performance for ACC and therefore is not 1543 
recommended in this setting {Tamhane, 2016 #248}.  1544 
 1545 
 1546 
R.6.3.6 We recommend assessment of residual adrenal function in patients with large 1547 
bilateral metastases. 1548 
 1549 
Reasoning 1550 
In rare cases, bilateral adrenal metastases can lead to adrenal insufficiency. Thus, in all 1551 
patients with potentially bilateral metastases, adrenal insufficiency should be considered and 1552 
clinically evaluated. If adrenal insufficiency seems to be possible, we recommend first to 1553 
measure a morning serum cortisol and plasma ACTH. In case of adrenal insufficiency, 1554 
plasma ACTH is clearly elevated in parallel to low cortisol. In uncertain cases, a synacthen 1555 
test should be performed {Bornstein, 2016 #211}.  1556 
If only one adrenal metastasis is present, adrenal insufficiency is extremely unlikely and we 1557 
recommend no specific assessment of adrenal reserve.  1558 
  1559 
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Figure 4: Evaluation of patients with adrenal mass and known extra-adrenal 1560 
malignancy 1561 
 1562 
1 Always take life expectancy in consideration. 1563 
2 If there is hormone excess, treat individualized. 1564 
3 FDG-PET/CT should be considered to exclude other metastatic deposits in patients with no other obvious 1565 
metastatic lesions for whom surgical removal of the lesion is an option. 1566 
  1567 
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6. Future directions and recommended research 1568 
 1569 
The NIH conference on the management of the clinically unapparent adrenal mass in 2002 1570 
formulated several research questions for future studies {Grumbach, 2003 #39}. Although 1571 
some of these issues have been addressed, only few questions have been conclusively 1572 
answered. From the current perspective we see need for clinical trials in all four areas 1573 
particularly addressed in the guideline (see section 3.5). Given that most recommendations 1574 
in this guideline are based on weak evidence, there is clearly room for studies aiming to 1575 
improve the evidence base of management of adrenal incidentalomas. 1576 
Among many important research questions, we selected five as particularly important. All of 1577 
them can only be answered in a collaborative interdisciplinary manner.  1578 
1) Large, cohort study in patients with an adrenal mass > 2 cm to investigate the most 1579 
suitable imaging methods to determine if an adrenal mass is benign or not. It will be crucial to 1580 
establish a definitive diagnosis either by histopathology or by long-term follow-up (> 2 years).  1581 
2) Large, long-term study to define whether or not ‘autonomous cortisol secretion’ is 1582 
associated with increased mortality and other hard clinical endpoints (e.g. myocardial 1583 
infarction or stroke). Such a study will also provide evidence for a suitable biochemical 1584 
definition of ‘autonomous cortisol secretion’.  1585 
3) Randomized trial on the potential benefit of surgery in patients with "autonomous cortisol 1586 
secretion". To make such a trial feasible it is probably wise to define a surrogate endpoint 1587 
(e.g. hypertension or type 2 diabetes) that can be well controlled (including standardized 1588 
treatment regimens) throughout the study. A similar trial could evaluate the value of drugs 1589 
targeting the cortisol excess.  1590 
4) Prospective study (laparoscopic vs. open surgery) in patients with potentially malignant 1591 
adrenal mass (<10 cm) without pre-operative evidence of local invasion and metastases to 1592 
learn which surgical approach is the most suitable one for this patient cohort.  1593 
5) We propose a long-term study with annual biochemical work-up of patients with adrenal 1594 
incidentalomas to clarify if such a long-term hormonal assessment is justified. This study 1595 
should also help to define the true incidence of relevant diseases like adrenocortical 1596 
carcinoma and pheochromocytoma among incidentalomas. 1597 
 1598 
Several other research questions deserve future research. Of particular importance seems to 1599 
us the establishment of biomarkers to determine non-invasively the origin of the adrenal 1600 
mass (adrenal cortex, medulla, extra-adrenal) and whether or not the mass is malignant. 1601 
Currently, urine steroid metabolomics for non-invasive and radiation free detection of a 1602 
malignant ‘steroid fingerprint’ in adrenocortical carcinoma patients {Arlt, 2011 #34} and the 1603 
combination of functional imaging methods (e.g. metomidate-based imaging and FDG-1604 
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PET/CT) are the most promising tools that should be further investigated. Similarly, for 1605 
patients with ‘autonomous cortisol secretion’ new methods to stratify on an individual basis to 1606 
intervention (or observation) are needed.   1607 
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Appendix  1624 
Table A1: Description of analyzed studies  1625 
Table A2: Results of the GRADE analyses 1626 
 1627 
Table A3: Selected drugs that may interfere with results of the dexamethasone 1628 
test* (adapted according {Nieman, 2008 #47}) 1629 
 
Drugs that accelerate dexamethasone metabolism by induction of CYP 3A4 
Phenobarbital 
Phenytoin 
Carbamazepine 
Primidone 
Rifampin 
Mitotane 
Rifapentine 
Ethosuximide 
Pioglitazone 
Drugs that impair dexamethasone metabolism by inhibition of CYP 3A4 
Aprepitant/fosaprepitant 
Itraconazole 
Ritonavir 
Fluoxetine 
Diltiazem 
Cimetidine 
Drugs that increase CBG and may falsely elevate cortisol results 
Estrogens 
Mitotane 
 
 
- * This should not be considered a complete list of potential drug interactions. 1630 
- Data regarding CYP3A4 obtained from http://medicine.iupui.edu/flockhart/table.htm.  1631 
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